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PREAMBLE
Aims
The clinical practice guidelines for the management of chronic 
hepatitis B (CHB) were first presented in 2004 by the Korean As-
sociation for the Study of the Liver (KASL), and were revised in 
2007 and 2011. The American Association for the Study of Liver 
Diseases (AASLD) published their guidelines in 2015, the Europe-
an Association for the Study of the Liver (EASL) in 2012, the Asian 
Pacific Association for the Study of the Liver (APASL) in 2015 and 
the World Health Organization (WHO) in 2015. These guidelines 
carry some variations due to ethnic differences and different med-
ical environments. Therefore, there is a demand for Korean prac-
tice guidelines which reflect medical practice in Korea. Problems 
with emergence of drug resistant mutation are eminent in Korea 
and the KASL updated their guidelines regarding the manage-
ment of antiviral resistant mutation in 2014.
In 2015, the objective of this manuscript was to update the rec-
ommendations for management of CHB, including epidemiology, 
prevention, natural history, diagnosis, treatment, monitoring, drug 
resistance mutations and treatment of special populations dis-
cussed herein based on current evidences or if, evidences lack, on 
expert opinions after deliberation. 
KASL clinical practice guidelines: management of 
chronic hepatitis B
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interquartile range; TACE, transcatheter arterial chemoembolization
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Target population
The main targets of this guideline are patients both newly diag-
nosed with CHB and those being followed up or treated for CHB. 
This guideline is also intended to facilitate management of pa-
tients under the following special circumstances: malignancy, 
transplantation, kidney dysfunctions, co-infection with other vi-
ruses, pregnancy, and children.
Intended users
This revised CHB guideline is designed as a resource for all Ko-
rean clinicians caring for patients with CHB. It also provides physi-
cians undertaking training courses with practical information on 
the management of CHB.
Developer and funding 
The CHB Clinical Practice Guideline Revision Committee (CP-
GRC) comprising 17 hepatologists and 1 pediatrician was formed 
with support from the KASL. All of the required funding was pro-
vided by the KASL. Each member of the CHB-CPGRC collected 
and evaluated evidence, and contributed to writing the manu-
script.
Conflicts of interest of the CHB-CPGRC members are summa-
rized in Conflicts of interest.
Evidence collection
Relevant evidences obtained from a comprehensive literature 
search using MEDLINE (up to 2015) were systematically reviewed 
and selected. The languages were limited to English and Korean. 
In addition to published articles, abstracts of important meetings 
published before 2015 were also evaluated. The following search 
terms were used: “hepatitis B”, “hepatitis B virus”, “HBV”, 
“chronic hepatitis”, and other key words related to clinical ques-
tions (see below). These clinical questions covered a variety of 
pertinent topics ranging from epidemiology, natural course, pre-
vention, diagnosis, treatment, antiviral resistance, and special sit-
uations.
Levels of evidence and grades of recommendation
The evidence and recommendations were graded according to 
Grading of Recommendations, Assessment, Development and 
Evaluation (GRADE) system with minor modifications (Table 1). 
The levels of evidence were determined as the possibility of 
change in the estimate of clinical effect by further research, and 
were described as high (A), moderate (B) or low (C). The grades of 
recommendation were either strong (1) or weak (2), as determined 
by the quality of evidence as well as patient-important outcomes 
and socioeconomic aspects.
List of the clinical questions
The committee considered the following questions as key com-
ponents to be covered in this guideline.
  1. How does this guideline differ from previous guidelines?
  2. What is the updated knowledge on the epidemiology?
  3.  What is the updated knowledge on the natural course of 
CHB?
  4. How should the infection be prevented?
  5. How are patients evaluated prior to treatment?
Table 1. Grading of Recommendations, Assessment, Development and Evaluation (GRADE)
Quality of evidence Criteria
High (A) Further research is unlikely to change confidence in the estimate of the clinical effect
Moderate (B) Further research may change confidence in the estimate of the clinical effect
Low (C) Further research is very likely to impact confidence on the estimate of clinical effect
Strength of recommendations Criteria
Strong (1)
Factors influencing the strength of the recommendation included the quality of the evidence, 
presumed patient-important outcomes, and cost
Weak (2)
Variability in preferences and values, or more uncertainty.
Recommendation is made with less certainty, higher cost or resource consumption
NOTE. Of the quality levels of evidence, we excluded “very low quality (D)” from the guidelines for convenience. This was originally included in the GRADE 
system and indicates that the estimate of effect is highly uncertain.
20 http://www.e-cmh.org
Clin Mol Hepatol
Volume_22  Number_1  March 2016
http://dx.doi.org/10.3350/cmh.2016.22.1.18
  6. When should treatment be considered?
  7. What are the goals and endpoints of treatment?
  8.  What are the optimal first-line treatments for different disease 
status?
  9. How should the treatment be monitored?
10. When can we consider stopping treatment?
11. What are the predictors of a treatment response?
12. What are the definitions of treatment failure? 
13. How should we manage drug-resistant CHB patients?
14.  What are the definitions of recurrence after treatment comple-
tion and how should these be managed? 
15. How should we manage the following special groups:
- acute hepatitis B
- liver transplantation
- chemotherapy/immunosuppression
- chronic kidney disease
-  coinfection [with hepatitis C virus (HCV), hepatitis D virus 
(HDV), and/or human immunodeficiency virus (HIV)]
16.  How can we reduce vertical transmission in pregnant CHB pa-
tients?
17. What is the optimal management of CHB in children?
Review of the manuscript
Drafts of the revised guideline were thoroughly reviewed at 
separate meetings of the committee. A revised manuscript was 
reviewed at a meeting of an external review board, and at a sym-
posium open to all KASL members, and was modified further prior 
to publication. The external review board comprised of 18 special-
ists in CHB who are members of the KASL. The final manuscript 
was endorsed by the board of executives of the KASL.
Release of the guidelines
The revised CHB guidelines of KASL were released on Novem-
ber 26, 2015 (http://www.kasl.org).
Plan for updates
Updates or full revision will be planned when major new evi-
dence regarding the diagnosis and/or treatment of CHB becomes 
available. Detailed plans for updates will be posted on the KASL 
website at a later date.
EPIDEMIOLOGY
Hepatitis B virus (HBV) infection, as a causative factor of liver 
disease of 240 million patients globally and death of 600 thou-
sand patients annually,1 is a major cause of acute and chronic 
hepatitis, liver cirrhosis, and hepatocellular carcinoma. It has been 
recognized as an important public health problem in Korea since 
the 1970s2 and was designated a third-class communicable dis-
ease by law in 1982 and is now the target of a national vaccina-
tion program as a second-class communicable disease.3  
The prevalence of HBV infection in the Korean population as es-
timated by positivity rates for hepatitis B surface antigen (HBsAg) 
was 8–9% for males and 5–6% for females before commercial-
ization of an HBV vaccine in the early 1980s;4 thereafter, the prev-
alence of HBV infection tended to decline gradually due to the ini-
tiation of a vaccination program for newborn infants in 1991 and 
a national vaccination program in 1995. For example, in 2006 the 
prevalence of HBV among children aged 4 to 6 years had de-
creased to 0.2%.5 Nevertheless, according to the 2005 National 
Health and Nutrition Examination Survey, the HBsAg positivity 
rate was 4.0% at 2009.6 The Ministry of Health and Welfare re-
ported that the HBsAg positivity rate was 3.4% for males and 
2.6% for females, with 3.0% of the total population being infect-
ed with HBV in 2012.7 Positivity rates for HBsAg among pregnant 
females, which represents a major infection route for hepatitis B, 
declined steadily after 2004, as did the positivity rates among fe-
males in the childbearing period.7 Given that HBsAg is detected in 
approximately 70% of patients with chronic hepatitis or cirrhosis,8 
and in 65–75% of HCC patients,9,10 it can be concluded that CHB 
infection is a matter of importance for public health in Korea. 
Most Korean CHB patients are infected with HBV genotype C2,11 
and tend to have lower hepatitis B e antigen (HBeAg) seroconver-
sion rates, more rapid progression to cirrhosis and HCC, reduced 
efficacy of interferon treatment, and are subject to higher rates of 
relapse after antiviral treatment, compared to those infected with 
other HBV genotypes.12,13
Natural history 
The progression of CHB may be divided into the following five 
clinical phases: the immune-tolerant phase, immune-active phase, 
immune-control phase, immune-escape phase, and HBsAg-clear-
ance phase. Individual patients do not necessarily experience 
these clinical phases in a continuous manner, and clinical phases 
are not always correlated with criteria or indications of antiviral 
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therapy.14,15 HBV DNA positivity indicates an acute or chronic HBV 
infection, and negativity indicates resolution of infection. For this 
reason, the WHO decided to delete the term ‘hepatitis B carrier.’ 
The natural history of CHB is outlined below (Table 2). 
1. Immune-tolerant phase
In cases of perinatal infection, the immune-tolerant phase is 
characterized by HBeAg positivity, high levels of serum HBV DNA 
(generally ≥107 IU/mL), normal levels of aspartate aminotrans-
ferase/alanine aminotransferase (AST/ALT), and mild or no liver 
necroinflammation.16-19 Elevation of ALT level was detected in 
16% of patients in the immune-tolerant phase during 5 years of 
follow up.19 
This phase may continue for more than three decades in pa-
tients infected with HBV genotype C, which is common among 
Korean patients, and the rate of spontaneous HBeAg loss is very 
low.20 Therefore, many females infected with this genotype are in 
the HBeAg-positive immune-tolerant phase when they are of 
childbearing age. The absence of, or only mild histologic liver 
damage, despite high levels of HBV DNA, is attributed to immune 
tolerance to HBV.21
2. Immune-active HBeAg-positive CHB
Most patients in the immune-tolerant phase will experience im-
mune responses to HBV as they grow older, and finally reach the 
immune-active phase, which is characterized by HBeAg positivity, 
lower serum HBV DNA levels, and increased or fluctuating ALT 
levels.22,23 Histologic findings in this phase include moderate-to-
severe liver inflammation and, in some patients, rapid progression 
of fibrosis.24 Such changes are due to enhancement of hepatitis B 
core antigen (HBcAg) or HBeAg-specific cytotoxic T-lymphocyte 
activity and the resulting destruction of infected hepatocytes.25 
Sustained HBV DNA suppression occasionally accompanies HBeAg 
seroconversion. 
Once HBeAg seroconversion occurs, the natural course of the 
disease may have one of three clinical features: (1) repeated 
HBeAg reversion and seroconversion, (2) inactive state, or (3) 
HBeAg-negative CHB.26,27 Typically, 10–40% of patients who ex-
perience seroconversion revert to HBeAg positivity and then expe-
rience recurrence of seroconversion at least once with progression 
of hepatitis activity.24,28,29 In particular, reversion frequently occurs 
in patients with HBV genotype C, and the rate decreases with 
age.20 Hepatic decompensation, which occurs in 5% of patients 
with acute exacerbation, may be fatal.30 
3. Immune-control inactive CHB
Most patients who seroconvert during the immune-active phase 
progress to the immune-control phase, which is characterized by 
HBeAg negativity, persistent normal ALT levels, and HBV DNA 
levels of <2,000 IU/mL.31-33 Typical histologic findings in this 
phase are mild liver inflammation and fibrosis;31 however, patients 
who have suffered from previous severe inflammation and fibrosis 
may continue to experience moderate-to-severe inflammation and 
fibrosis. This may result in even biochemical and histologic tests 
not being useful for differentiating these patients from those with 
cirrhosis who require antiviral treatment.32 
This phase persists for a long time in most patients, but with a 
relatively good prognosis; however, an estimated 20% of them 
Table 2. Natural course of chronic hepatitis B (CHB)
Clinical phase Serum marker ALT HBV-DNA Histology
Immune-tolerant phase HBeAg (+) Persistently normal High level of viral replication Minimal histological disease
Immune-active phase,
HBeAg-positive CHB
HBeAg (+);
may develop anti-HBe
Raised or intermittently 
raised ALT
Lower level of viral replication
Histological necroinflammatory 
activity present
Lobular hepatitis, bridging fibrosis 
and fibrosis may be present
Immune-control phase
Inactive CHB
HBeAg (-)
anti-HBe (+)
Persistently normal ALT
Low or undetectable HBV 
DNA (HBV DNA levels 
≤2,000 IU/mL)
Risk of cirrhosis and HCC reduced
Immune-escape phase,
HBeAg-negative CHB
HBeAg (-), with or 
without being anti-
HBe positive
Raised ALT (persistent 
or intermittent 
exacerbations
Moderate to high levels of 
HBV replication (HBV DNA 
levels >2,000 IU/mL)
Older persons especially at risk 
for progressive disease (fibrosis/
cirrhosis)
HBsAg-clearance phase
HBsAg (-)
anti-HBc (+)
anti-HBs (+/-)
Normal Not detected
ALT, alanine aminotransferase; HBV, Hepatitis B virus; HCC, hepatocellular carcinoma.
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will reactivate to the HBeAg-negative or HBeAg-positive immune-
active phase, and might experience recurring periods of reactiva-
tion and inactivation throughout their lives, which can lead to cir-
rhosis or HCC.34,35 This is why the ALT levels of patients in the 
immune-control phase must be measured at least every 6 months 
for life because currently there are no predictors of which patients 
will remain in the inactive phase and which will revert to HBeAg-
negative active hepatitis.15
4. Immune-escape HBeAg-negative CHB
Approximately 20% of patients who experience HBeAg sero-
conversion during their immune-active phase maintain HBeAg 
negativity and hepatitis B e antibody (anti-HBe) positivity but 
progress to the immune-escape phase, with findings of HBV DNA 
levels ≥2,000 IU/mL, increased ALT levels, and active liver necro-
inflammation.26 These patients show HBeAg negativity since they 
harbor HBV variants in the precore (PC) or basal core promoter 
(BCP) regions of HBV DNA, resulting in failure to produce 
HBeAg.36-38 HBeAg-negative CHB is associated with low rates of 
prolonged spontaneous disease remission, and most patients in 
this phase will experience persistent hepatocellular inflammation 
and progress to hepatic fibrosis and cirrhosis.38-40 Severe fluctua-
tions of HBV DNA and ALT levels can make it difficult to differen-
tiate these patients from those in the immune-control phase.41 
Accordingly, for the first year after a patient is diagnosed as being 
in the immune-control phase, HBV DNA and ALT levels should be 
measured every 3 months to identify HBeAg-negative CHB pa-
tients who require antiviral treatment.15,42
5. HBsAg-clearance phase
Patients in the immune-control phase subsequently progress to 
the HBsAg clearance phase at a rate of 1–2% annually.41,43,44 Ac-
cording to Liaw’s data, HBsAg loss occurs in 1.9% of CHB pa-
tients, and 0.8% of those with chronic HBV infection regardless 
of gender and virus genotype, with age being the only known in-
fluencing factor.45,46 It has been reported that Korean patients ex-
perience a relatively low rate of HBsAg loss (0.4% annually).47 
HBV DNA is not detectable in the serum during this phase, while 
hepatitis B core antibody (anti-HBc) with or without hepatitis B 
surface antibody (anti-HBs) is detectable. HBsAg loss is associated 
with a reduced risk of cirrhosis but a sustained, significant risk of 
HCC development.34,43,48-53
Risk factors that influence the natural history of CHB
The accumulated incidence of cirrhosis developing from CHB is 
generally reported to be 8–20%.54,55 In Korea, the reported annual 
and 5-year accumulated incidences of cirrhosis are 5.1% and 23%, 
respectively, while those for HCC are 0.8% and 3%.54 The risk fac-
tors for hepatitis B progressing to cirrhosis or HCC can be divided 
into demographic, environmental, social, and viral factors (Table 3).56 
Regarding demographic factors, the risk of developing HCC is 
Table 3. Risk factors associated with the development of hepatocellular carcinoma (HCC) and/or cirrhosis in persons with chronic hepatitis B
 Increased risk of HCC Increased risk of cirrhosis
Demographic   
     Male sex 3+ +
     Increasing age >40 years 3+ 3+
     Family history of HCC 3+ +
Social and environmental   
     Alcohol + +
     Aflatoxin 3+ Unknown
     Smoking + +
     Coffee Decreased risk of HCC Slower progression of liver fibrosis
Viral factor   
     Genotype C 3+ 2+
     HBV DNA >2,000 IU/mL 3+ 3+
     BCP mutation 3+ +
BCP, basal core promoter; HBV, hepatitis B virus.
Modified from McMahon.56
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three- to fourfold higher for males than for females, and the risk 
of HCC and cirrhosis is low among those younger than 40 years, 
then increases exponentially with increasing age after the fourth 
decade of life.33,57-59 Those with a family history of HCC also have 
a higher risk of contracting HCC.60,61 Environmental and social risk 
factors for progression to cirrhosis or HCC are alcohol consump-
tion, exposure to aflatoxin,62 and smoking.63 It is suggested that 
obesity, metabolic syndrome, and fatty changes in histologic tests 
increase the risk of CHB patients progressing to hepatic fibrosis or 
HCC.64-67 Many epidemiological research studies have found that 
coffee exerts protective effects against the development of hepat-
ic fibrosis and HCC.68-72 
Viral factors that may influence the progression of CHB patients 
to cirrhosis or HCC include high levels of serum HBV DNA 
(≥20,000 IU/mL), genotype C, BCP variants, and coinfection with 
other viruses.57,59,73-75 According to the Taiwanese Risk Evaluation 
of Viral Load Elevation and Association Liver Disease/Cancer-Hep-
atitis B Virus (REVEAL-HBV) study, the risk of developing HCC 
during the study period among subjects aged at least 40 years 
was significantly higher in those with an HBV DNA level of ≥104 
copies/mL (cpm) at the start of observation and 105 cpm 11 years 
later than among those with an entry HBV DNA level of 
<104 cpm. Likewise, the incidence of cirrhosis was significantly 
associated with HBV DNA levels higher than 104 cpm at study 
entry.58,59 If the HBV DNA level decreased during the follow-up 
period, the risk of developing HCC or cirrhosis decreased. Subse-
quent research highlighted the clinical importance of careful eval-
uation of patients with an HBV DNA level >2,000 IU/mL who are 
older than 40 years (especially those HBeAg positive) for the de-
velopment of fibrosis 57 and HCC.74,75 Therefore, intervention with 
antiviral therapy should be performed when appropriate, as rec-
ommended by established practice guidelines.56 
Unlike HCV infection, the HBV genotype exerts a profound ef-
fect on the clinical outcome but—with the exception of interfer-
on—little effect on the treatment outcome.76 Eight HBV geno-
types have been identified, and that with the worst prognosis is 
genotype C, which is the most common in Korean CHB patients.77 
Genotype C is associated with delayed natural seroconversion and 
rapid progression to liver cirrhosis and HCC. Therefore, it is an in-
dependent risk factor for HCC development. According to a cohort 
study in Alaska, patients infected with A-, B-, and D-genotype 
hepatitis B typically experience seroconversion from HBeAg to an-
ti-HBe before the age of 20 years, whereas in those infected with 
the C genotype this occurs at a mean age of 47 years.20 This im-
plies that those infected with genotype C would on average expe-
rience a much longer period of infection with high HBV viral 
loads, and may in part explain why the risks of HCC and cirrhosis 
are so high in patients infected with genotype C. 
Two important genetic mutations of HBV that affect the natural 
history of CHB infection are the BCP and PC mutations.42,45,75,77-79 
BCP mutations are A1762T and G1764A mutations in the HBV 
BCP regions, and multiple cross-sectional and prospective studies 
have indicated that they increase the risks of cirrhosis and 
HCC.42,45,77,78 According to the results of the REVEAL-HBV study, 
359 and 1,149 individuals without and with BCP mutations, re-
spectively, developed HCC among a population of 100,000.80 PC 
mutation typically appears near the time of HBeAg seroconver-
sion. The mutation results in an amino-acid change that creates a 
stop codon at site 1896 on the HBV genome, which results in the 
virus being able to transcribe hepatitis B core protein but not 
HBeAg.45 Patients infected with PC mutants are characterized by 
HBeAg negativity and HBeAg positivity, but high levels of HBV 
DNA.81,82 However, the observed effects of PC mutants on the 
natural history of CHB have been inconsistent; a recent analysis of 
the role of PC in the prospective population-based REVEAL-HBV 
study revealed the opposite to the findings of cross-sectional clin-
ic-based studies—that the presence and absence of the PC muta-
tion decreased and increased, respectively, the subsequent annual 
incidence of HCC (269 and 996 per 100,000, respectively).80 
PREVENTION
Because HBV infection is endemic in Korea, any person at 
high risk of liver disease or has suspected liver disease is recom-
mended to have their HBsAg and anti-HBs statuses checked.14 
CHB patients can transmit virus to others, and hence they should 
be counseled regarding how to modify their lifestyle so as to pre-
vent HBV transmission. Epidemiologic studies found that the daily 
consumption of 40–80 g of alcohol is associated with liver dam-
age and the progression of liver disease,83-88 and a long-term 
prospective cohort study of patients with chronic HBV infection 
showed that alcohol consumption increases the risks of liver cir-
rhosis and HCC development.57,59 No data are available on the 
threshold level of alcohol consumption required to significantly 
increase the risks of liver cirrhosis and HCC in patients with 
chronic HBV infection. In the general population, a daily alcohol 
intake of 24 g in males and 12 g in females significantly increas-
es the risk of liver cirrhosis.89  So, abstinence or a very limited 
consumption of alcohol is recommended in patients with chronic 
24 http://www.e-cmh.org
Clin Mol Hepatol
Volume_22  Number_1  March 2016
http://dx.doi.org/10.3350/cmh.2016.22.1.18
HBV infection.89 According to a long-term prospective study of 
patients with chronic HBV infection, smoking also increases the 
risks of liver cirrhosis and HCC, and so non-smoking is recom-
mended in patients with chronic HBV infection.57,59,90
Vertical infection is the most important route of HBV trans-
mission. Following initiation of the HCV vaccination program, 
the HBsAg positivity rate among pregnant females was 3.32% 
(308/9281) and the vertical transmission rate was 1.59% (4/252) 
in 2014. Therefore, the vaccination program is effective for control 
of vertical transmission.91 HBV immunoglobulin and vaccination 
after delivery can prevent 90-95% of vertical transmission to 
newborns from HBsAg-positive mothers.92-94 Therefore, such in-
fants should receive 0.5 mL HBIG and scheduled HBV vaccina-
tion within 12 hours of birth and after. Adding immunoglobulin 
is more effective than vaccination only. The introduction of HBV 
vaccination did not result in the rate of HBV infection among 
newborns differing between breast- and formula-feeding HB-
sAg-positive mothers (0% vs. 3%, respectively).95
In patients negative for HBsAg and anti-HBs, vaccination is rec-
ommended. Isolated anti-HBc positive patients negative for HB-
sAg and anti-HBs should consider vaccination, especially if liver 
function results are abnormal. As HBV is endemic in Korea, pa-
tients negative for HBsAg and anti-HBs should be vaccinated,92,93 
particularly the household members and sexual partners of pa-
tients with chronic HBV infection, as such persons are at increased 
risk of HBV infection.96,97 Patients with chronic HBV infection are 
not candidates for vaccination because of its lack of effectiveness. 
Sexual partners who have not been tested for HBV serologic 
markers, have not completed the full immunization series, or who 
are negative for anti-HBs should use barrier protection methods, 
such as condoms. The three doses constituting the hepatitis B 
vaccine series administered intramuscularly at 0, 1, and 6 months 
induce a protective antibody response (anti-HBs >10 mIU/mL) in 
>90% of recipients. Most non-responders (44–100%) subse-
quently respond to a further three-dose revaccination.92,93 
Although serologic testing for anti-HBs is not necessary after 
routine vaccination in immunocompetent adults, post-vaccination 
testing of anti-HBs status is recommended in some subjects, such 
as newborns of HBV-infected mothers or 9-18 months old young 
infants whose family members has CHB. Healthcare workers, dial-
ysis patients, workers in dialysis units and operation rooms, im-
munocompromised subjects (e.g., HIV infection, hematopoietic 
stem cell transplants, patients with chemotherapy), and sexual 
partners of patients with chronic HBV infection should be tested 
1-2 months after their completion of the HBV immunization se-
ries.92,93 While anti-HBs levels can decline or disappear over several 
decades, vaccinated subjects remain protected against HBV infec-
tion and there is no need for booster vaccination in immunocompe-
tent individuals. However, an anti-HBs level of <10 mIU/mL in di-
alysis patients indicates an increased risk of HBV infection, and so 
a booster vaccination is needed if annual testing reveals an anti-
HBs level of <10 mIU/mL.92 This also applies to immunocompro-
mised patients.92,93 A person without protective anti-HBs exposed 
to HBV-contaminated blood or body fluids should receive hepatitis 
B immunoglobulin (HBIG, 0.06 mL/kg) and hepatitis B vaccine as 
soon as possible; preferably within 24 h, otherwise postexposure 
prophylaxis should be initiated within 7 days for percutaneous ex-
posure or within 14 days for sexual exposure.98 
Coinfection with hepatitis A in HBV carriers increases the risk of 
mortality by 5.6- to 29-fold.99 Therefore, hepatitis A vaccination is 
recommended for persons negative for the protective hepatitis A 
virus antibody (anti-HAV).100
[Recommendations]
1.  HBV vaccination is recommended for persons negative for 
HBsAg and anti-HBs. (A1)
2.  Abstinence from alcohol and smoking is recommended for 
patients with chronic HBV infection. (A1)
3.  Newborns of HBV-infected mothers should receive HBIG 
and hepatitis B vaccine at delivery and complete the recom-
mended vaccination series. (A1)
4.  Hepatitis A vaccine should be given to patients with chronic 
HBV infection negative for anti-HAV. (A1)
DIAGNOSIS AND INITIAL EVALUATION
CHB is defined as the presence of HBsAg for longer than 6 
months. The initial evaluation of CHB patients should include a 
thorough history-taking and physical examination, with empha-
sis on risk factors such as alcohol consumption or drug use, 
HAV, HCV, HDV coinfection, and family history of HBV infection 
and HCC. The causal relationship between HBV infection and 
liver disease has yet to be established. Appropriate longitudinal 
long-term follow-up is crucial for patients with CHB. Serologic 
tests, virologic tests, biochemical tests and/or liver biopsy are 
used to assess HBV replication and the degree of liver injury in 
patients with CHB. 
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Antigen/antibody test
HBsAg immunoassay is a necessary and accurate test for di-
agnosis of CHB. By definition, patients who remain positive for 
HBsAg for longer than 6 months have progressed to chronic infec-
tion. Quantitative measurement of HBsAg is now possible and the 
combination of HBsAg quantification and HBV DNA level is an in-
tegral component of monitoring the response to antiviral therapy. 
Serologic tests, including anti-HBs and anti-HBc, can assist in 
screening of populations for HBV infection and differentiating 
among acute, chronic, and past infections. In acute HBV infec-
tion, HBsAg appears 1-10 weeks after exposure to HBsAg and 
disappears 4-6 months after recovering from HBV infection.101 
Acute HBV infection is diagnosed by being HBsAg positive and 
anti-HBc IgM positive. Anti-HBc IgM is the only marker present 
during the window period, the interval between disappearance of 
HBsAg and appearance of anti-HBs.
Anti-HBc typically persists for life, but IgM anti-HBc is detect-
able for 6 months, and anti-HBc is detectable thereafter in pa-
tients with resolved acute HBV infection. IgM anti-HBc can be de-
tected at low levels during chronic HBV infection.93  Persistently 
positive anti-HBc is shown when anti-HBs titer from the past HBV 
infection becomes undetectable over time or in cases with occult 
hepatitis B infection.102-105 Measurement of the serum HBV DNA 
level might be helpful in these settings. Patients with these sero-
logic patterns should be followed with repeated testing of HBsAg, 
anti-HBs, and anti-HBc for 3–6 months. Patients who recover 
from HBV infection will test negative for HBsAg and positive for 
anti-HBs and anti-HBc. Patients who respond adequately to hepa-
titis B vaccines will test negative for anti-HBc and positive for anti-
HBs, since anti-HBc emerges only after HBV infection and persists 
for life.
Laboratory tests for patients with CHB should include HBeAg 
and anti-HBe. HBeAg positivity generally indicates a high level 
of viral replication, and anti-HBe positivity a low level. Serum 
HBV DNA and AST/ALT levels are important parameters in 
HBeAg-negative patients. HBeAg-negative, anti-HBe-positive 
patients with a normal ALT level and an HBV DNA level of 
<2,000 IU/mL (<10,000 cpm) may be in the inactive phase. 
These patients usually have mild or no liver necroinflammation 
and no or slow progression of fibrosis, but some patients with 
severe liver damage during the immune-active phase may pres-
ent with a cirrhotic liver. HBeAg-negative CHB patients have an 
elevated ALT and an HBV DNA level of >2,000 IU/mL. HBe-neg-
ative CHB is associated with viral mutants in the PC and/or BCP 
regions that are unable to produce or produce only low levels of 
HBeAg.40 They have severe liver necroinflammation with a low 
rate of prolonged spontaneous disease remission and a high risk 
of subsequent complications, such as decompensated cirrhosis 
and HCC.106
Acute hepatitis A co-infection in chronic hepatitis B patients 
can result in increased icteric manifestation, longer recovery 
time, and increased risk of fulminant hepatic failure. Underlying 
chronic liver disease is an important risk factor for fulminant he-
patic failure and death in patients with acute HAV infec-
tion.106-108 Therefore, CHB patients younger than 50 years should 
undergo testing for IgG anti-HAV, and all patients with a nega-
tive immune status for hepatitis A should receive HAV vaccine. 
Laboratory tests should include tests for coinfection with HCV 
and/or HIV in those at risk.
Serum HBV DNA test
Serum HBV DNA testing provides a direct measure of the level 
of viral replication. This quantification is essential for characteriz-
ing the status of infection, diagnosing the disease, making the 
decision to treat, and subsequent monitoring of patients. It is also 
important for predicting the risks of cirrhosis and HCC. Therefore, 
it should be applied to all patients diagnosed with CHB. The intro-
duction of the international unit (IU) (1 IU is equivalent to 5.6 HBV 
DNA copies) as a recommended reporting unit for HBV DNA has 
facilitated standardized reporting and comparison of serum HBV 
DNA levels.109 The methods used to quantify HBV DNA levels have 
evolved rapidly. Real-time PCR-based assays have been intro-
duced and demonstrate both high sensitivity and a broad linear 
range (10–108 IU/mL) of quantification.110 The same test should be 
specified each time when monitoring HBV DNA levels for a given 
patient in clinical practice to ensure consistency. 
HBV genotypes
HBV genotypes appear to influence the progression of dis-
ease, risk of HCC, and response to therapy (including interferon 
therapy).75,111,112 Some studies in Asia have suggested that geno-
type C is associated more frequently with HBV reactivation, se-
vere liver disease, and HCC than is genotype B.111,113-115 The spe-
cific genotype has also been shown to affect the response to 
interferon therapy, with the rate of an antiviral response to pe-
gylated interferon (peginterferon) therapy being higher for gen-
otypes A and B than for genotypes C and D.116 In CHB, examina-
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tion of genotyping is recommended selectively to help identify 
patients who might be at greater risk of disease progression, 
and routinely to determine the most appropriate candidates for 
peginterferon therapy.117 However, genotyping is recommended 
as being unnecessary in Korea because Korean patients are al-
most exclusively infected with genotype C.
Biochemical test
Assessments of the severity of liver disease should include 
biochemical markers such as AST, ALT, gamma-glutamyl trans-
peptidase (GGT), alkaline phosphatase (ALP), prothrombin time 
(PT), and serum albumin. A progressive decline in the serum al-
bumin level and prolongation of the PT, often accompanied by a 
decrease in the platelet count, are characteristically observed 
after cirrhosis develops. The serum ALT level has been common-
ly used in assessments of liver disease and as an important cri-
terion for defining which patients are candidates for therapy.118 
The ALT level is usually higher than that of AST, but the ratio 
may be reversed when the disease progresses to cirrhosis. HBV-
infected patients with normal or mildly elevated ALT levels have 
been thought to have mild-to-no or significant necroinflamma-
tion on liver biopsy, respectively. However, there is no correla-
tion between the degrees of liver cell necrosis and ALT level.119 
ALT activity might also be affected by other factors such as 
body mass index, gender, abnormal lipid and carbohydrate me-
tabolism, and uremia.119,120 Therefore, relying solely on the find-
ing of elevated ALT as a prerequisite for treatment candidacy 
has limitations. Data from clinical studies have shown that the 
true normal level of ALT is significantly lower than the previously 
established limits: 40 IU/mL for males and 30 IU/mL for females. 
Moreover, data from cohort studies indicate that the upper limit 
of normal (ULN) ALT and AST levels should be decreased to 
30 IU/mL for males and 19 IU/mL for females.119,120 Clinical stud-
ies have shown that patients with ALT levels of 40–45 IU/mL 
have a high risk of significant liver disease and mortality from 
complications.121 According to the treatment algorithm for CHB 
suggested by Keefee et al., serum ALT levels of 30 and 19 IU/mL 
for males and females, respectively, should be used as the ULN 
levels when deciding to commence treatment.117 Further pro-
spective studies are needed to clarify this issue.
A recent prospective study in Korea involving 2,000 liver donors 
suggested that healthy serum ALT values should be 33 IU/L for 
males and 25 IU/L for females.122 Ninety thousand males and 
40,000 females aged 35 to 59 years in the prospective NHS co-
hort exhibited upper limits of AST and ALT values for prediction of 
liver diseases of 31 IU/L and 30 IU/L, respectively.121
Liver biopsy
A liver biopsy is recommended for determining the degree of 
necroinflammation and fibrosis in patients with elevated ALT, an 
HBV DNA positive or both, because liver histology is useful 
when deciding whether or not to commence treatment. A liver 
biopsy is invasive but the rate of serious complications is very 
low (1/4,000-10,000).123 Several recent clinical studies found 
that 12–43% of patients with persistent normal ALT levels had 
histologic evidence of significant fibrosis or inflammation in a 
biopsy, particularly those older than 35-40 years.116-121,124 A ret-
rospective study of the relationship between ALT level and fi-
brosis in CHB patients reported similar results: of the 59 pa-
tients with persistent normal ALT levels, 18% had stage 2 
fibrosis and 34% had grade 2 or 3 inflammation, with 37% of 
all patients with persistent normal ALT levels having significant 
fibrosis and inflammation.125 Subgroup analysis also demon-
strated that most of the patients with fibrosis had high normal 
ALT levels. These results indicate that the ALT level in CHB pa-
tients with high normal ALT levels should be interpreted in con-
junction with the serum HBV DNA level, age, and liver histology 
results when deciding to commence treatment. Therefore, in 
HBsAg-positive patients with HBV DNA levels of ≥20,000 IU/mL 
and normal ALT levels, a liver biopsy should be considered in 
those older than 35 years since they are less likely to be in the 
immune-tolerance phase of infection. Treatment should be con-
sidered if a liver biopsy reveals fibrosis at stage 2 or greater 
and/or necroinflammation. When deciding whether to com-
mence treatment in this patient population, it must be recog-
nized that long-term therapy is likely to be needed due to the 
low probability of HBeAg seroconversion occurring within 1 
year. A liver biopsy is usually not required in patients with clini-
cal evidence of cirrhosis or when treatment is indicated irrespec-
tive of the grade of activity or the stage of fibrosis. This is be-
cause only a small portion of the liver is sampled, and the low 
intra/interobserver reliabilities. Therefore, the efficacy of nonin-
vasive methods such as the Fibroscan device or serum markers 
in assessing fibrosis in CHB has increased.
Noninvasive fibrosis test
The severity of liver fibrosis and determination of ALT and HBV 
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DNA levels have essential roles in treatment decisions. Noninva-
sive methods to estimate liver fibrosis have been developed and 
used. These methods include the aspartate aminotransferase-
platelet ratio index (APRI), AST/ALT ratio (AAR), Forns’ fibrosis in-
dex (age, platelets, GGT, cholesterol), FIB-4 (platelets, ALT, AST, 
Age). Also, the FibroTest that uses indirect markers (α-2 macro-
globulin, haptoglobin, r-globulin, apolipoprotein A1, and GGT), 
the FibroSpect II Enhanced Liver Fibrosis test that uses direct 
markers (Hepascore, FibroMeter, hyaluronic acid and tissue inhibi-
tor of matrix metalloproteinase-1, 2) are available.126 The age-
spleen-platelet ratio index (ASPRI) is the most accurate in predict-
ing liver fibrosis in chronic HBV infection.127 APRI is useful for 
diagnosis of not only for liver fibrosis but also liver cirrhosis, while 
FIB4 is useful for mild fibrosis. However FIB4 has limitations in 
terms of predicting fibrosis of stage F2 and above as it has low 
sensitivity and specificity.126
Transient elastography using Fibroscan® has a high degree of 
accuracy for assessment of advanced liver fibrosis. It is the most 
commonly used method for chronic liver diseases because of its 
noninvasiveness and high reproducibility.128 
 Fibroscan® can be perform rapidly (5 min) in the outpatient 
clinics of hospitals and produce a result immediately after the 
test.129,130 However, only procedures involving ≥10 successful mea-
surements are considered reliable. Moreover, a success rate (SR) 
of at least 60% and an interquartile range (IQR) of less than 30% 
of the median value are required (Interquartile range/median val-
ue (IQR/M),131 Fibroscan® has limitations in subjects with ascites, 
obesity, or narrow intercostal spaces. Moreover, the system may 
yield false-positive results in subjects with acute hepatitis and ex-
trahepatic biliary tract obstruction.132-134 
Fibroscan® has greater diagnostic accuracy than APRI or FIB-4 
for liver cirrhosis in a study that compared liver biopsy, AAR, 
APRI, Fibroscan®, and FIB-4 in patients with chronic hepati-
tis.135,136 Also, Fibroscan® was more predictive of liver fibrosis and 
liver cirrhosis in a study that compared Fibroscan® and APRI in 
567 subjects with chronic hepatitis (Area under Receiver Operat-
ing Characteristic: F3 0.849 vs. 0.812, F4 0.902 vs. 0.707).137
Screening for hepatocellular carcinoma
The initial evaluation of patients with CHB should include tests 
for HCC. Periodic surveillance is also needed in these patients to 
ensure early detection of HCC during follow-up. The issue of HCC 
is treated in detail in the “Practical Guidelines for Management of 
Hepatocellular Carcinoma 2014.”138 Standard tools for HCC 
screening include measuring the α-fetoprotein level and ultra-
sound. Magnetic resonance imaging and computed tomography 
might be preferred for some patients with severe cirrhosis or obe-
sity, since ultrasound has poor sensitivity in those conditions. Pa-
tients at a high risk of HCC include those older than 40 years,139 
patients with cirrhosis, those with a family history of HCC, and 
any carriers older than 40 years exhibiting persistent or intermit-
tent ALT elevation, a high HBV DNA level (>2,000 IU/mL), or 
both.14 Keeffe et al. recently recommend earlier screening (at 30–
35 years of age or even younger) in Asian patients with presumed 
infection at the time of birth or in early childhood due to the high-
er risk of HCC in this patient population.
The use of antiviral therapies improves liver function and in-
creases survival rates of patients with liver failure (liver decom-
pensation).
Consistent inhibition of HBV replication with antiviral therapies 
delays progression of liver fibrosis, induces reversal of advanced 
liver fibrosis, reduces the incidence of liver cirrhosis, and prevents 
diseases including hepatocellular carcinoma in patients with ad-
vanced liver fibrosis or liver cirrhosis.140
Recently developed treatments can decrease the incidence of 
liver diseases or delay their progression but cannot prevent all 
possible complications. Therefore, surveillance and screening for 
hepatocellular carcinoma are required at regular intervals for early 
diagnosis and a complete recovery.
[Recommendations] 
1. The initial evaluation of patients with CHB should include a 
thorough history-taking and physical examination, with 
emphasis on risk factors such as coinfection, alcohol con-
sumption, and the family history of HBV infection and liver 
cancer. (A1)
2. Laboratory tests to assess liver disease should include the 
complete blood count (CBC), AST/ALT, ALP, GGT, bilirubin, 
albumin, creatinine, and PT. (A1)
3. Tests for HBV replication include HBeAg/anti-HBe and 
quantitative serum HBV DNA levels. A real-time PCR quanti-
fication assay is strongly recommended for quantifying the 
HBV DNA level. (A1)
4. An anti-HCV test is necessary to rule out coinfection with 
HCV. (B1)
5. An anti-HAV test is necessary in CHB patients younger than 
50 years. (A1)
6. Liver biopsy is useful for determining the degree of liver in-
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flammation and fibrosis. (A1)
7. Noninvasive tests such as serum markers and liver elasticity 
are used for diagnosis of the degree of liver fibrosis. (B1)
8. Standard tools for HCC screening include ultrasound and 
serum α-fetoprotein measurement. (A1)
TREATMENT GOALS
The goals of hepatitis B treatment are to decrease the mortality 
rate and increase the survival rate by alleviating hepatic inflam-
mation and preventing the development of fibrosis, which ulti-
mately reduces the frequency of progression of hepatitis to liver 
cirrhosis or HCC.141-145 The optimal treatment result would be the 
loss or seroconversion of HBsAg, but since intranuclear cccDNA 
persists despite treatment, complete clearance of HBV is almost 
impossible to achieve.146 This is why indices such as ALT level nor-
malization, undetectable HBV DNA, loss or seroconversion of 
HBeAg, and histologic improvement are used (rather than the loss 
or seroconversion of HBsAg) to predict the treatment response in 
the clinical context. Therefore, a realistic virologic goal of anti-
HBV therapy is the suppression of viral replication. 
Most guidelines state that antiviral treatment is required for pa-
tients with acute liver failure, decompensated liver cirrhosis or in 
the acute phase of severe chronic HBV hepatitis regardless of HBV 
DNA and ALT levels, and the treatment has almost no complica-
tions, although few controlled studies have been performed.147 
Antiviral therapy decreases the rate of recurrence of viral infection 
in patients who require liver transplantation.148 The HBV DNA and 
HBeAg levels in CHB are indices of viral replication and active 
hepatitis, respectively, and patients with HBeAg-positive hepatitis 
B with high levels of HBV DNA have an increased risk of develop-
ing liver cirrhosis or HCC.57,59,74 Patients with disappearance or 
conversion of serum HBeAg have a low risk of liver cirrhosis and 
hepatocellular carcinoma, and so have a good prognosis.26,149
The loss or seroconversion of HBeAg during the natural course 
of hepatitis B or after IFN-α treatment indicates a favorable long-
term outcome with a decreased probability of liver cirrhosis or 
HCC development.26,53,149,150 Therefore, clearance or seroconver-
sion of HBeAg is an important goal of antiviral treatment in pa-
tients with HBeAg-positive active hepatitis. A decrease in the HBV 
DNA level has recently been suggested to be even more impor-
tant. The decrease in the HBV DNA level after antiviral treatment 
in active hepatitis with elevated HBV DNA levels results in histo-
logic improvement, seroconversion of HBeAg, and normalization 
of ALT levels, and thus a slowing of the progression of hepati-
tis.151,152 However, even in cases with HBV DNA levels of less than 
104 copies/mL, which is considered to be inactive hepatitis, the 
hepatitis can still progress to liver cirrhosis and HCC. Therefore, a 
decrease in HBV DNA to an undetectable level is recommended 
for patients on antiviral treatment.153
 [Recommendations]
1. The treatment goals in hepatitis B are to decrease the mor-
tality rate and increase the survival rate by alleviating he-
patic inflammation and preventing the development of fi-
brosis, which would ultimately reduce the frequency of 
progression of hepatitis to liver cirrhosis or HCC. (A1)
2. To achieve HBsAg clearance, which is the ideal treatment 
goal, long-term maintenance of an undetectable HBV DNA 
level is recommended. (B1)
3. The ultimate treatment goals in patients with HBeAg-posi-
tive hepatitis are normalization of the ALT level, undetect-
able HBV DNA level, and the clearance or seroconversion of 
HBsAg and HBeAg. In patients with HBeAg-negative hepa-
titis the treatment goals are normalization of the ALT level, 
an undetectable HBV DNA level, and the clearance or sero-
conversion of HBsAg. (B1)
TREATMENT INDICATIONS AND STRATEGIES
Long-term viral suppression by drugs with potent antiviral activ-
ity and high genetic barrier to resistance is a current paradigm of 
antiviral treatment for CHB aimed at the prevention of disease 
progression and improvement of survival. Since eradication of 
HBV infection is rarely achieved with currently available drugs, 
long-term treatment is necessary in most cases. Treatment proto-
col should be individualized according to various factors: host fac-
tors such as mode of infection, disease status, and immunity; viral 
factors such as genotypes, prior antiviral treatment, mutation, 
and susceptibility level; and drug factors such local availability, 
cost, and reimbursement policy.35 The durations of currently avail-
able antiviral trials are insufficient to assess the effects of treat-
ment on long-term survival.35 Long-term treatment with oral 
nucleos(t)ide analogs (NAs) ameliorates histologic abnormalities 
such as necroinflammation and/or fibrosis, both in HBeAg-posi-
tive35,154,155 and HBeAg-negative155-158 CHB. Therefore, long-term 
antiviral therapy may prevent disease progression and reduce the 
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risk of liver cirrhosis.145
Immune tolerance phase
Antiviral therapy is not indicated for patients in the immune-tol-
erant phase despite HBeAg positivity and a high level of HBV 
DNA, because of the benign natural course of the disease and 
such treatment results in minimal histologic changes.159 
[Recommendations]
Patients in the immune-tolerant phase (HBeAg positive and 
persistently normal ALT level as recommended by this guide-
line rather than local laboratory ULNs) are not indicated for 
antiviral therapy. (B1)
Chronic hepatitis B
CHB patients with active viral replication and significant inflam-
mation and/or fibrosis are appropriate targets for antiviral treat-
ment. Early guidelines generally agreed that antiviral treatment 
could be recommended for CHB patients (especially those without 
liver cirrhosis) with serum HBV DNA level > 20,000 IU/mL and se-
rum ALT level> 2 ULN.160,161 However, recent guidelines suggest 
that the indications of antiviral treatment should be expanded to 
those with lower serum HBV DNA levels and/or lower serum ALT 
levels.35,162,163 
Serum HBV DNA level is a marker of viral replication and an in-
dicator of the efficacy of antiviral treatment in individuals with 
CHB. Progression to cirrhosis in HBV-infected patients is reported 
to be strongly correlated with the level of circulating virus.57,59 
However, an HBV DNA level of 105 cpm or 20,000 IU/mL was ar-
bitrarily chosen by early guidelines as the cut-off level for indica-
tion of antiviral treatment. Some patients with lower serum HBV 
DNA levels (300–105 cpm), especially those with HBeAg negative 
hepatitis and/or cirrhosis, frequently show progression of liver dis-
ease and hence may need treatment.35,161,164 A serum HBV DNA 
level of ≥20,000 IU/mL has been suggested as the cut-off for 
HBeAg-positive CHB.164 However, the distinction between HBeAg-
negative CHB and inactive carriers is not clear due to the fluctuating 
course of HBeAg-negative CHB.164 A population-based cohort study 
revealed increased risks of liver cirrhosis and HCC when the serum 
HBV DNA level exceeds 2,000 IU/mL,57,59,165 therefore this level is 
widely accepted as the cut-off for indicating antiviral therapy.
Serum ALT has been used as a convenient surrogate marker for 
liver injury, and elevated serum ALT is indicated as a risk factor for 
disease progression in CHB.57 A serum ALT level > 2 ULN was 
suggested as a suitable indication of antiviral treatment for CHB 
by early guidelines, especially in CHB patients without cirrho-
sis.160,161,166 However, an increased risk of developing liver cirrhosis 
and HCC has been documented in patients with mildly elevated 
serum ALT and even in those with serum ALT levels in the upper 
normal range.119,121,167 About two-thirds of CHB patients with mild-
ly elevated ALT (1–2 ULN) show significant hepatic fibrosis (F2 or 
higher),168 and CHB patients with persistently normal ALT levels 
and HBV DNA levels of >20,000 IU/mL may actually have signifi-
cant fibrosis or inflammation,125,168,169 which are indications for an-
tiviral therapy. A cohort study in Hong Kong demonstrated that 
the risk of liver-related complications in CHB patients was higher 
for ALT levels of 0.5–1 ULN and 1–2 ULN than for those <0.5 
ULN. Thus, previous ALT criteria might exclude some patients with 
existing or potentially significant disease.170,171
Liver biopsy has three major roles: diagnosis, assessment of 
prognosis (disease staging), and assistance in making therapeutic 
decisions.172 In CHB, liver biopsy is especially useful for patients 
who do not meet definite criteria for treatment but still have a 
possible risk of significant disease.35 Age of the patient, serum 
HBV DNA level, serum ALT level, and family history of HCC should 
be considered before deciding whether to perform a biopsy. ALT 
and HBV DNA levels may miss cases of histologically significant 
disease,169 and so histologic confirmation should be considered, 
especially in patients of advanced age with serum AST/ALT levels 
in the upper normal range or higher.
Peginterferon-α and NAs including lamivudine, adefovir, clevu-
dine, telbivudine, entecavir, and tenofovir, have been used for an-
tiviral treatment of CHB. Drug of choice can differ according to 
various factors, including effectiveness, safety, risk of resistance, 
and cost of drugs, preference of patients and physicians, and any 
plans for pregnancy.35 
Lamivudine and telbivudine are not preferred due to their weak 
antiviral potency and high frequency of drug resistance, unless a 
good response is predicted or the anticipated duration of treat-
ment is short. Adefovir is not an ideal option due to its weak anti-
viral activity and high frequency of drug resistance after 48 
weeks. There are insufficient long-term follow-up data on the ef-
ficacy and safety of clevudine. Entecavir and tenofovir are safe 
agents with potent antiviral effects and low frequency of drug re-
sistance. Due to convenience of usage, peginterferon-α is pre-
ferred over interferon-α. To date, there has been no report con-
firming the superiority of combination therapies over monotherapy 
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in treatment-naïve patients. 
Currently, monotherapy with entecavir, tenofovir, or peginterferon-α 
is the preferred initial therapy for CHB. Other NAs might be used in 
patients with good predictors of response, and can be continued or 
modified according to on-treatment response. 
In patients treated with lamivudine, the predictive factors for a 
good response to therapy are increased initial serum ALT level and 
high histologic activity index score.118 During telbivudine treat-
ment, a combination of pretreatment characteristics (low HBV 
DNA level; HBV DNA < 109 copies/mL (HBeAg positive CHB) or 
HBV DNA < 107 copies/mL (HBeAg negative CHB) and ALT level ≥ 
2 ULN ) plus non-detectable serum HBV DNA at treatment week 
24 is suggested to be the strongest predictor of optimal outcomes 
at 2 years.173 Of CHB patients receiving lamivudine or telbivudine 
treatment, those with a virologic response at week 24 (< 300 
copies/mL) achieved a high rate of HBeAg seroconversion at week 
52.125 Less resistance was reported in patients with low serum 
HBV DNA levels (< 1,000 copies/mL) at week 48 during long-term 
therapy with adefovir.157 
[Recommendations]
HBeAg-positive CHB
1. HBeAg positive CHB patients with HBV DNA ≥ 20,000 IU/
mL, plus serum AST or ALT ≥ 2 ULN or significant histologic 
changes such as inflammation or fibrosis (≥ moderate 
necroinflammation; ≥ periportal fibrosis) on biopsy should 
be considered for treatment. (A1) Treatment can be delayed 
for 3–6 months if spontaneous HBeAg seroconversion is 
expected. (B2) However, patients with apparent or antici-
pated liver failure (i.e., those with jaundice, prolonged PT, 
hepatic encephalopathy, and ascites) should be treated 
promptly. (B1) 
2. For those with HBV DNA ≥ 20,000 IU/mL and serum AST or 
ALT < 2 ULN, observation or liver biopsy can be considered. 
Antiviral treatment is recommended for those showing 
subsequent elevation of serum ALT or AST, or significant 
histologic changes such as inflammation or fibrosis on bi-
opsy. (A1)  
3. Monotherapy with tenofovir, entecavir, or peginterferon-α 
is preferred. (A1) 
HBeAg-negative CHB
1. HBeAg negative CHB patients with HBV DNA ≥ 2,000 IU/mL 
plus serum AST or ALT ≥ 2 ULN or significant pathologic 
changes such as inflammation or fibrosis on biopsy should 
be considered for treatment. (A1)  
2. For those with HBV DNA ≥ 2,000 IU/mL and serum AST or ALT 
< 2 ULN, observation or liver biopsy can be considered. Anti-
viral treatment is recommended for those showing subse-
quent elevation of serum ALT or AST, or significant pathologic 
changes such as inflammation or fibrosis on biopsy. (A1)  
3. Monotherapy with tenofovir, entecavir, or peginterferon-α 
is preferred. (A1) 
Compensated liver cirrhosis
Liver biopsy has been considered the gold standard for diagno-
sis of liver cirrhosis. Whereas use of liver biopsy is limited in real 
clinical practice; imaging studies such as CT, abdominal ultra-
sound, and MRI are helpful for the diagnosis of liver cirrhosis. 
Typical image findings of liver cirrhosis include nodular liver sur-
face, splenomegaly, and the presence of intra-abdominal collater-
al vessels, which indicate increased portal venous pressure. If 
esophageal or gastric varices is observed in upper gastrointestinal 
endoscopy, liver cirrhosis can be diagnosed.174 With imaging stud-
ies, laboratory findings such as albumin, bilirubin, or prothrombin 
time and platelet values are helpful for the diagnosis of liver cir-
rhosis.
Patients with compensated cirrhosis and elevated serum HBV 
DNA (HBV DNA ≥ 2,000 IU/mL) can benefit from treatment with 
long-term oral NAs, because such treatment may prevent disease 
progression141 and the development of HCC.144,145,175-178 Compen-
sated cirrhosis patients with a low viral load, although HBV DNA 
< 2,000 IU/mL, are at considerable risk for HCC, and antiviral 
treatment in these patients was suggested to reduce the risk of 
HCC.179 Antiviral therapy is recommended in CH-B patients with 
significant hepatic fibrosis regardless of AST/ALT levels.35,162,163,180 
The levels of AST/ALT should not be used as criteria for starting 
antiviral therapy in patients with liver cirrhosis, because they al-
ready have significant hepatic fibrosis and frequently have nearly 
normal AST/ALT levels.
In a cohort of HBeAg-positive liver cirrhosis patients, long-term 
follow-up data after interferon-α therapy showed that the HBeAg 
seroconversion rate was similar (67% vs. 60%, respectively) but 
the ALT normalization rate (62% vs. 47%) and HBsAg loss rate 
(23% vs. 3%) were better in the interferon-α treated group than 
in the control group.181 Interferon-α treatment in cirrhotic patients 
requires careful monitoring because it may cause acute exacerba-
tion of hepatitis, which leads to hepatic failure.182 After treating 
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CHB patients with peginterferon-α-2b alone or in combination 
with lamivudine for 52 weeks, the virologic response rate (as indi-
cated by HBeAg seroconversion and an HBV DNA level of 
<10,000 copies/mL) was superior in those with cirrhosis than in 
those without cirrhosis (35% vs. 14%, respectively).183 However, 
acute exacerbation of hepatitis (33% vs. 12%, respectively) and 
requirement for dose reduction (63% vs. 30%) were more com-
mon in cirrhotic patients than in noncirrhotic patients.183 There-
fore, interferon-α can be used with caution in cirrhotic patients 
with preserved liver function. 
In patients with decompensated liver cirrhosis, long-term lami-
vudine treatment significantly reduced the complications and he-
patocellular carcinoma compared to placebo. However, the benefit 
was less in patients with lamivudine resistance.141 Entecavir treat-
ment of patients with advanced hepatic fibrosis or cirrhosis for 48 
weeks showed improvements in the liver histology in 57%, 59%, 
and 43% of patients with HBeAg-positive, HBeAg-negative, and 
lamivudine-resistant CHB, respectively.184 A study including a 
small number (n=40) of patients showed that telbivudine effec-
tively decreased HBV DNA levels in patients with compensated 
liver cirrhosis, and HBV DNA was undetectable after 48 weeks of 
telbivudine treatment in 92.5%.185 A study comparing the effects 
of clevudine treatment for 48 weeks found that the virologic re-
sponse rate (HBV DNA <1,000) (87.1% vs. 71.4%, respectively) 
and biochemical response rate (83.9% vs. 80.9%) did not differ 
significantly between patients with CHB (n=21) and those with 
liver cirrhosis (n=31).186 A phase III clinical trial of tenofovir adopt-
ing paired liver biopsy at baseline and at week 240 revealed that, 
of the 96 (28%) patients with liver cirrhosis (Ishak score 5 or 6) at 
baseline, 71 (74%) no longer had liver cirrhosis (≥1 unit decrease 
in score) at follow-up biopsy.187
Since long-term antiviral therapy is generally required in pa-
tients with liver cirrhosis, the AASLD and EASL guidelines recom-
mend the use of entecavir or tenofovir due to their potent antiviral 
efficacy and high genetic barrier to drug resistance. 
Decompensated liver cirrhosis
Decompensated liver cirrhosis is defined as liver cirrhosis com-
plicated with ascites, variceal bleeding, hepatic encephalopathy, 
or jaundice.174 Patients with decompensated liver cirrhosis should 
be treated at an institution that can provide appropriate manage-
ment for complications of liver cirrhosis. Liver transplantation 
should be considered in patients with decompensated liver cirrho-
sis. Oral NAs may improve hepatic function 142 and decrease the 
need for liver transplantation in Child-Turcotte-Pugh (CTP) class C 
cirrhosis.188 The use of interferon-α in patients with decompensat-
ed liver cirrhosis is contraindicated due to the risk of serious com-
plications, such as infection or hepatic failure.189 Lamivudine treat-
ment for longer than 6 months was shown to improve or stabilize 
liver function and prolong the time to liver transplantation in pa-
tients with decompensated liver cirrhosis.190-192 A study comparing 
the effects of telbivudine and lamivudine in patients with decom-
pensated liver cirrhosis found a higher rate of HBV DNA undetect-
ability (47% vs. 36%, respectively) and a lower viral breakthrough 
rate (29% vs. 39%, respectively) in the telbivudine group than in 
the lamivudine group.193 A study of the effect of adefovir in lami-
vudine-resistant cirrhotic patients (n=101) found that the virologic 
response rate was lower in decompensated cirrhotic patients 
(n=53) than in compensated cirrhotic patients (n=48) (50.9% vs. 
83.3%, respectively), whereas ALT normalization and HBeAg loss 
did not differ between the two groups.194 
A randomized study comparing the effects of entecavir (1 mg/
day) and adefovir (10 mg/day) in patients with decompensated 
liver cirrhosis found that the rates of HBV DNA undetectability at 
weeks 24 and 48 were higher in the entecavir group than in the 
adefovir group (week 24, 49% vs. 16%, respectively; week 48, 
57% vs. 20%), while HBeAg seroconversion at week 48 did not 
differ significantly between the two groups (6% vs. 10%).195 Ente-
cavir therapy showed improvement of the CTP score (to ≥2) in al-
most half (27/55) of treatment-naïve patients with decompensat-
ed liver cirrhosis (n=55) and a 1-year transplantation-free survival 
rate of 87.1%.142 
A randomized trial comparing the effects of tenofovir (n=45), 
tenofovir plus emtricitabine (n=45), and entecavir (n=22) in pa-
tients with decompensated liver cirrhosis showed that the require-
ment for early withdrawal of drug (6.7%, 4.4%, and 9.1%, re-
spectively) and elevation of serum creatinine (8.9%, 6.7%, and 
4.5%) did not differ among the three groups. The rates of HBV 
DNA undetectability at week 48 were 70.5%, 87.8%, and 72.7%, 
respectively, and those of HBeAg loss/seroconversion were 
21%/21%, 27%/13%, and 0%/0%.143
Because prompt treatment is required in patients with decom-
pensated liver cirrhosis, oral antiviral therapy is the treatment of 
choice if HBV DNA is detectable by PCR tests.35,162,180 An antiviral 
drug with a potent antiviral efficacy and high genetic barrier to 
drug resistance should be used. Since clinical improvement often 
requires 3–6 months of antiviral therapy, progression to hepatic 
failure is possible even during antiviral therapy in some patients. 
Hence, liver transplantation should be considered together with 
32 http://www.e-cmh.org
Clin Mol Hepatol
Volume_22  Number_1  March 2016
http://dx.doi.org/10.3350/cmh.2016.22.1.18
antiviral treatment.192 Pre- and post-transplantation antiviral ther-
apy has been reported to reduce the risk of reactivation of hepati-
tis after liver transplantation. 
[Recommendations]
Compensated liver cirrhosis 
1. Antiviral therapy should be performed if HBV DNA level is 
≥2,000 IU/mL regardless of AST/ALT levels. (A1)
2. Antiviral therapy can be considered when HBV DNA is HBV 
DNA is <2,000 IU/mL to reduce the risk of decompensation 
regardless of AST/ALT levels. (C1)
3. Oral antiviral therapy is recommended. Monotherapy with 
tenofovir or entecavir is preferred. (A1)
4. Peginterferon-α may be used with careful monitoring of 
impairment of liver function and drug side effects in pa-
tients with compensated liver cirrhosis with preserved liver 
function. (B2)
Decompensated liver cirrhosis
1. Prompt antiviral therapy is recommended if HBV DNA is de-
tectable by PCR test regardless of AST/ALT levels. (B1)
2. Oral antiviral therapy is recommended. Monotherapy with 
tenofovir or entecavir is preferred. (A1) 
3. The use of peginterferon-α is contraindicated due to the 
risk of serious complications, such as hepatic failure. (A1)
4. Liver transplantation should be considered. (B1)
TREATMENT MONITORING
Monitoring prior to antiviral treatment
After diagnosis and initial evaluation of patients with CHB, their 
serum HBV DNA, ALT, HBeAg, and anti-HBe levels should be reg-
ularly monitored until they are considered for treatment.35,168,196,197 
The HBV genotype test is not recommended in Korea because 
most Korean patients are known to have HBV genotype C.198,199 
Applying a quantitative HBsAg (qHBsAg) assay before or during 
antiviral treatment may assist prediction of the treatment re-
sponse.200-203 HBsAg is generated by transcription and translation 
of cccDNA or HBV DNA integrated into the genome, and can be 
detected on the surface of infective virions and on circular and 
linear non-infective particles. The quantity of HBsAg (qHBsAg) 
showed a positive correlation with the amount of cccDNA in he-
patocytes, which enabled a standardized qHBsAg assay.204,205 HB-
sAg quantity is highest during the immune-tolerant phase (4.5–
5.0 log10 IU/mL), starts to decrease during the immune-active 
phase (3.0–4.5 log10 IU/mL), and decreases gradually after HBeAg 
seroconversion. The HBsAg quantity is lowest in the immune-con-
trol phase (1.5–3.0 log10 IU/mL), and starts to increase in HBeAg-
negative CHB (2.5–4.0 log10 IU/mL).
206-208 During long-term lami-
vudine treatment, a low level before treatment and large 
decrement during treatment of qHBsAg were predictors of HBsAg 
seroconversion. Several studies reported that the decrement of 
qHBsAg correlated with the decrement of HBV DNA level.203,209,210
[Recommendations]
1.  Chronic hepatitis (HBeAg positive or negative)
1)  In patients with persistently normal AST/ALT levels, liver 
function should be tested and serum HBV DNA should be 
measured by real-time PCR at 2–6-month intervals, plus 
HBeAg status (HBeAg and anti-HBe) should be checked ev-
ery 6–12 months. (C1)
2) If AST/ALT levels increase above the normal limit, liver 
function should be tested every 1–3 months, and serum 
HBV DNA should be measured by real-time PCR plus 
HBeAg status should be checked every 2–6 months. (C1)
2.  Compensated liver cirrhosis
 Liver function should be tested every 2–6 months, and se-
rum HBV DNA should be measured by real-time PCR plus 
HBeAg status should be checked every 2–6 months. (C1)
3.  Decompensated liver cirrhosis
 Liver function should be tested every 1–3 months, and se-
rum HBV DNA should be measured by real-time PCR plus 
HBeAg status should be checked every 2–6 months. (C1)
Monitoring during antiviral treatment
1. NAs
In a compliant patient with a primary non-response (decrease in 
serum HBV DNA of <2 log10 IU/mL after 6 months or more of NA 
treatment), changing to or adding a more-potent drug should be 
considered. Serum HBV DNA should be measured every 1 to 
3 months for the first few months to ascertain the virologic re-
sponse, and then every 3 to 6 months. Serum HBV DNA reduction 
to an undetectable level by real-time PCR (i.e., <10–15 IU/mL) 
should ideally be achieved to avoid resistance. Serum HBV DNA 
monitoring is thus critical to detect treatment failure.
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Peginterferon therapy resulted in a more significant reduction in 
qHBsAg levels than NA therapy.211,212 However, a low pretreat-
ment qHBsAg level and greater qHBsAg decline were reported to 
be positive predictors of a sustained virologic response.213,214  In 
CHB patients receiving 10 years of NA therapy, low baseline qHB-
sAg levels (<1,000 IU/mL) and a greater rate of HBsAg reduction 
(>0.166 log10 IU/mL/year) were predictive of qHBsAg seroclear-
ance, strengthening the prognostic role of HBsAg measurements 
during NA therapy.203 Compliance and antiviral-resistance muta-
tions should be monitored in patients who develop virologic 
breakthrough while receiving NA, and an appropriate rescue ther-
apy should be initiated if necessary.215-219
Most NAs are excreted through the kidney, and hence dose ad-
justment is required in patients with renal insufficiency (Table 4),35 
Table 4. Nucleos(t)ide analogue dosage adjustment for adult patients with altered creatinine clearance 
Creatinine clearance (mL/min)a Recommended dose
Nucleoside analogues
Lamivudine
≥50 100 mg q 24 h
30-49 100 mg first dose, then 50 mg q 24 h
15-29 100 mg first dose, then 25 mg q 24 h
5-14 35 mg first dose, then 15 mg q 24 h
<5 35 mg first dose, then 10 mg q 24 h
Telbivudine
≥50 600 mg q 24 h
30-49 600 mg q 48 h
<30 (not requiring dialysis) 600 mg q 72 h
End-stage renal diseaseb 600 mg q 96 h
Entecavir NA naïve Lamivudine refractory/resistant
≥50 0.5 mg q 24 h 1 mg q 24 h
30-49 0.25 mg q 24 h or 0.5mg q 48 h 0.5 mg q 24 h or 1 mg q 48 h
10-29 0.15 mg q 24 h or 0.5mg q 72 h 0.3 mg q 24 h or 1 mg q 72 h
< 10 or hemodialysisb or continuous 
ambulatory peritoneal dialysis
0.05 mg q 24 h or 0.5mg q 7 days 0.1 mg q 24 h or 1mg q 7 days
Nucleotide analogues
Adefovir
≥50 10 mg q 24 h
20-49 10 mg q 48 h
10-19 10 mg q 72 h
<10 No recommendation
Hemodialysisb 10 mg q 7 days following dialysis
Tenofovir
≥ 50 300 mg q 24 h
30-49 300 mg q 48 h
10-29 300 mg q 72-96 h
<10 with dialysisc 300 mg q 7 days or after a total of approximately 12 h of dialysis
<10 without dialysis No recommendation
aCalculated using ideal (lean) body weight.
bAdminister after hemodialysis.  
cGenerally once weekly assuming three hemodialysis sessions per week of approximately 4 h duration. Administer following completion of dialysis. 
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and regular monitoring of renal function should be performed in 
patients receiving adefovir or tenofovir. Several reports have associ-
ated tenofovir with bone loss in patients with HIV, although there 
was no consistent report during tenofovir monotherapy.220-222 
Studies of entecavir-related carcinogenicity are in progress. 
There have been few reports on telbivudine-related myositis; 
however, monitoring of the serum creatine kinase (CK) level is 
recommended due to the possibility of CK elevation.223-226 For 
clevudine prescription, serum CK level and related symptoms 
should be monitored due to clevudine-related myositis and CK el-
evation.227-229 
2. Peginterferon-α
The serum CBC and ALT level of patients receiving peginterferon-α 
should be tested monthly. Serum HBV DNA should be measured af-
ter 3–6 months of treatment to verify the primary response. For re-
sponse prediction, qHBsAg assay can be used before the treat-
ment and at 12 and 24 weeks of treatment. All patients treated 
with peginterferon-α should be checked for the known adverse 
effects of interferon at every visit.
HBeAg-positive CHB
Patients should be tested for HBeAg and anti-HBe at 6 and 12 
months during the treatment, and at 6 months post treatment. 
After cessation of treatment, patients should be monitored for 
6–12 months to check if additional treatment is required. There is 
a high probability of HBsAg loss if serum HBV DNA becomes un-
detectable during treatment. HBeAg-positive patients who achieve 
HBeAg seroconversion with peginterferon-α require a long follow-
up due to the possibility of HBeAg reversion or development of 
HBeAg-negative CHB. HBsAg loss should be checked at 6-month 
intervals after HBeAg seroconversion if serum HBV DNA is unde-
tectable. The qHBsAg assay assists in predicting the treatment re-
sponse.230,231 In case of a primary non-response (failure to achieve a 
1 log10 reduction in serum HBV DNA from baseline after 3 months 
of peginterferon-α treatment), peginterferon-α treatment should 
be stopped and replaced by a NA. Several studies recommend that 
peginterferon-α treatment should be stopped if qHBsAg does not 
decrease below 20,000 IU/mL after 24 weeks of treatment, which 
is predictive of non-response.230,231
HBeAg-negative CHB
HBeAg-negative patients should be monitored similarly to 
HBeAg-positive patients during 48 weeks of treatment. A virolog-
ic response with a serum HBV DNA level of <2,000 IU/mL is gen-
erally associated with remission of the liver disease.231 Undetect-
able serum HBV DNA by real-time PCR is the ideal off-treatment 
sustained response, with a high probability of HBsAg loss in the 
longer term. HBsAg should be checked at 6-month intervals if 
HBV DNA is not detectable. qHBsAg levels after 12 and 24 weeks 
of treatment as well as serum HBV DNA levels can be major pre-
dictive factors of a treatment response.210,232,233 Several studies 
recommend treatment interruption when qHBsAg after 12 weeks 
of treatment does not decrease, together with a < 2 log10 serum 
HBV DNA level.234,235
[Recommendations]
1. During treatment with NAs, liver function should be tested 
and serum HBV DNA should be measured by real-time PCR 
every 1–3 months, plus HBeAg status (HBeAg and anti-
HBeAg) should be checked every 3–6 months. (C1) qHBsAg 
assay may assist prediction of the treatment response and 
identification of cases in which discontinuation of antiviral 
therapy may be attempted. (C1) 
2. During treatment with peginterferon-α, CBC and ALT level 
should be measured monthly. Serum HBV DNA should be 
measured by real-time PCR at 1- to 3-month intervals, plus 
HBeAg and anti-HBe should be checked at 6 and 12 months 
during the treatment and at 6 months post-treatment. (C1) 
qHBsAg assay should be performed before, at 12 and 24 
weeks during the treatment and at the end of treatment. (B1)
3.  After identification of a complete virologic response, serum 
HBV DNA should be measured by real-time PCR after 3–6 
months and then retesting should be performed at 2–3 
months after HBeAg seroclearance is achieved. (C1)
4. Patients who develop virologic breakthrough while receiv-
ing a NA should be monitored for compliance and antiviral-
resistance mutations. (A1)
5.  During antiviral therapy, close monitoring for side effects of 
each drug is mandatory. (A1)
Monitoring after antiviral treatment
The response to antiviral treatment persists in some patients, while 
others relapse. Non-responders should prepare for the deterioration 
of liver function. Therefore, regular monitoring is needed to check for 
the durability of the treatment response, relapse, and liver function. 
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[Recommendations]
1. During the first year after the cessation of antiviral treat-
ment, liver function should be monitored and serum HBV 
DNA should be measured by real-time PCR every 1–3 
months, plus HBeAg and anti-HBe should be checked at 3- 
to 6-month intervals. Beyond 1 year after the cessation of 
antiviral treatment, liver function and serum HBV DNA by 
real-time PCR should be tested every 3–6 months to detect 
viral relapse. (C1)
2. For early detection of HCC, ultrasound and serum 
α-fetoprotein measurement should be performed regu-
larly. (A1)
CESSATION OF TREATMENT
HBeAg-positive CHB
Although the ideal goal of treatment is to achieve HBsAg loss, 
the primary endpoint when treating patients with HBeAg-positive 
hepatitis is to achieve HBeAg seroconversion. Undetectable serum 
HBV DNA by real-time PCR and HBeAg seroconversion are strong-
ly correlated with favorable biochemical and histologic responses. 
NA can be stopped when HBeAg seroconversion is achieved and 
antiviral treatment has been maintained at least for 12 months.236 
However, cessation should be decided carefully since 40–90% of 
patients developed reactivation of HBeAg-positive or -negative 
hepatitis after HBeAg seroconversion induced by NA treat-
ment.237-240 HBsAg should be tested at 6-month intervals after 
HBeAg seroconversion. HBsAg loss is rarely observed after NA 
therapy; however, low baseline qHBsAg levels and greater rate of 
HBsAg reduction were highly predictive of HBsAg seroclear-
ance.203 Peginterferon-α is generally administered for 48 weeks, 
and its efficacy was confirmed in a recent double-blind, random-
ized controlled study.241,242 
HBeAg-negative CHB
The recommended duration of peginterferon-α treatment in pa-
tients with HBeAg-negative hepatitis is 48 weeks, but the optimal 
treatment duration for NA is unknown, and cessation of treat-
ment should be individually decided according to the clinical 
treatment response and the baseline severity of the liver disease. 
Treatment with NA should be continued until the loss of HBsAg. 
Treatment discontinuation can be considered if undetectable se-
rum HBV DNA has been documented on three separate occasions 
6 months apart.163 However, close follow up is required due to the 
high probability of reactivation (29.7–91.0%) after treatment dis-
continuation.239,243-245 Peginterferon-α administration for 48 weeks 
is recommended.
Liver cirrhosis
Long-term treatment is required in patients with cirrhosis. In 
HBeAg-positive patients with compensated cirrhosis, treatment dis-
continuation can be considered when NA is administered for at 
least a further 12 months after HBeAg seroconversion. Treatment 
discontinuation can be considered after achievement of HBsAg loss 
in HBeAg-negative patients. Monitoring for viral relapse and acute 
exacerbation of disease is mandatory after discontinuation. Long-
term treatment should be planned in patients with decompensated 
cirrhosis, including the possibility of liver transplantation.
[Recommendations]
1. HBeAg-positive CHB
1) The optimal duration of treatment with a NA is unclear, al-
though the ideal goal is HBsAg loss, and alternative goals 
are HBeAg loss and seroconversion. NAs should be admin-
istered at least 12 months after serum HBV DNA is unde-
tectable and HBeAg seroclearance or seroconversion is at-
tained. (B1) 
2) Peginterferon should be administered for 48 weeks. (A1)
2. HBeAg-negative CHB
1) Although the optimal duration of treatment with NA is un-
clear, discontinuation of NA treatment may be considered 
when HBsAg loss is demonstrated. (A1) 
2) Peginterferon-α should be administered for at least 48 
weeks. (B1)
3. Liver cirrhosis
 Patients require long-term treatment. (B1) 
DEFINITIONS OF RESPONSE AND PREDIC-
TORS OF RESPONSE
Definitions of treatment responses (Table 5)
The definitions of responses to antiviral therapy vary according 
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to the type of therapy. 
1. NA
A primary non-response to NA is defined as a decrease of less 
than 2 log10 IU/mL in serum HBV DNA from baseline after 6 
months of therapy. A complete virologic response  is defined as 
undetectable serum HBV DNA by real-time PCR. A partial virolog-
ic response is defined as a decrease in serum HBV DNA of more 
than 1 log10 IU/mL but with serum HBV DNA still being detectable 
by real-time PCR.246 A partial virologic response should be as-
sessed to determine whether to modify the current therapy after 
24 weeks of treatment for moderately potent drugs or drugs with 
a low genetic barrier to resistance (lamivudine and telbivudine), 
and after 48 weeks of treatment for highly potent drugs, drugs 
with a high genetic barrier to resistance, and drugs with late 
emergence of resistance (e.g., entecavir, adefovir, and tenofovir).
Virologic breakthrough is defined as a confirmed increase in se-
rum HBV DNA of more than 1 log10 IU/mL relative to the nadir se-
rum HBV DNA during therapy. This usually precedes a biochemical 
breakthrough, which is characterized by an increase in ALT level 
after an initial normalization. If a virologic breakthrough develops 
in a compliant patient, antiviral-resistant mutations should be 
tested for. 
Genotypic resistance is defined as the presence of HBV mutations 
in serum that confers resistance to the antiviral agent, and pheno-
typic resistance is defined as the presence of HBV mutations that 
decrease susceptibility to antiviral drugs in an in vitro test. Cross-
resistance is defined as an HBV mutation induced by one antiviral 
agent that confers resistance to other antiviral agents.
HBV resistance to NAs is characterized by the presence of HBV 
variants with amino-acid substitutions that confer reduced suscep-
tibility to the administered NA. Such resistance may result in prima-
ry treatment failure or virologic breakthrough during therapy.
2. Peginterferon-α
A primary non-response to peginterferon-α is defined as a de-
crease of less than 1log10 IU/mL in serum HBV DNA from baseline 
after 3 months of therapy. A virologic response is defined as an 
HBV DNA level of less than 2,000 IU/mL after 6 months of thera-
py. A serologic response is defined by HBeAg seroconversion in 
patients with HBeAg-positive CHB.
 
Predictors of treatment responses 
Certain baseline and on-treatment predictors of the subsequent 
treatment response have been identified. The predictors of the re-
sponses to existing antiviral therapies at various time points vary 
according to the agent.
1. NAs
Pretreatment factors predictive of HBeAg seroconversion are a 
low viral load (serum HBV DNA of <107 IU/mL), high ALT level (<3 
ULN), and high inflammatory activity score in a liver biopsy (at 
least A2)247 A high pretreatment ALT level is the most important 
Table 5. Definitions of responses to antiviral therapy of CHB patients
Category of response
Nucleos(t)ide analogues
Primary non-response Decrease in serum HBV DNA <2 log10 IU/mL after 6 months of therapy
Partial virologic response Decrease in serum HBV DNA of more than 2 log10 IU/mL but detectable HBV DNA by real-time PCR assay
Complete virologic response Decrease in serum HBV DNA to an undetectable level by real-time PCR assay
Virologic breakthrough Increase in serum HBV DNA of more than 1 log10 IU/mL compared to nadir (lowest value)
Biochemical breakthrough Increase in serum ALT level after ALT normalization on antiviral therapy
Genotypic resistance Detection of HBV mutations known to confer antiviral resistance during antiviral therapy
Phenotypic resistance
Decreased susceptibility (in vitro  testing) to inhibition by antiviral drugs associated with genotypic 
resistance
Cross resistance HBV mutation selected by one antiviral agent that also confers resistance to other antiviral agents
Peginterferon alpha
Primary non-response Decrease in serum HBV DNA <1 log10 IU/mL after 3 months of peginterferon alpha therapy
Virologic response Decrease in serum HBV DNA of less than 2,000 IU/mL after 6 months of peginterferon alpha therapy
Serologic response HBeAg seroconversion in patients with HBeAg-positive chronic hepatitis B
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predictor of the outcome of treatment with lamivudine, adefovir, 
or telbivudine.118 During treatment with lamivudine, adefovir, or 
telbivudine, a virologic response at 24 or 48 weeks (undetectable 
serum HBV DNA by a real-time PCR assay) is associated with lower 
incidences of antiviral resistance (i.e., higher probability of a sus-
tained virologic response) and HBeAg seroconversion in HBeAg-
positive patients.156,225,248 HBV genotype does not influence the re-
sponse to any NA. In a study of the ability of qHBsAg assay to 
predict a treatment response, both HBsAg ≤2 log IU/mL and reduc-
tion by >1 log from baseline at the end of treatment had a 78% 
positive predictive value and 96% negative predictive value for a 
12-month sustained post-treatment response (HBV DNA ≤200 IU/
mL) to lamivudine in HBeAg-negative patients.249 During telbivu-
dine treatment, a decline in serum HBsAg levels (≥ 1 log10 IU/mL) in 
the first year was related to a greater likelihood of achieving HB-
sAg clearance at year 3.202 Serum HBsAg levels ≤2 log IU/mL at 
treatment week 104 are highly predictive of sustained virologic 
response to telbivudine at 2 years off-treatment.250 
2. Peginterferon-α
Pretreatment factors predictive of HBeAg seroconversion in 
HBeAg-positive patients are a high ALT level, low viral load, a 
high inflammatory activity score in a liver biopsy, and HBV geno-
type.183,251 There is no consensus among previous reports for pa-
tients with HBeAg-negative hepatitis, but generally a pretreat-
ment high ALT level, young age, and female gender are reported 
to be associated with a favorable treatment response.124,252
A decrease in serum HBV DNA to less than 20,000 IU/mL after 
12 weeks of treatment is associated with a 50% probability of 
HBeAg seroconversion in HBeAg-positive patients and with a 
50% probability of a sustained response in HBeAg-negative pa-
tients.124,253 A decrease in HBeAg at week 24 may predict HBeAg 
seroconversion.118,253 In HBeAg-positive patients, HBsAg levels 
<1,500 IU/mL at week 12 during peginterferon alfa-2a therapy 
were associated with high rates of posttreatment response, but 
treatment discontinuation is indicated in all patients with HBsAg 
>20,000 IU/mL at week 24.230,231 In HBeAg-negative patients, at 
week 12 of peginterferon-α treatment, the combination of a de-
cline in serum HBV DNA <2 log10 copies/mL and absence of a de-
crease in HBsAg levels is predictive of a poor response.234,235 HBV 
genotypes A and B are associated with a better response to 
interferon-α than genotype C, in terms of HBeAg seroconversion 
and HBsAg loss.254-257 However, knowledge of the HBV genotype 
has a poor predictive value in individual cases, and currently gen-
otype alone should not determine the choice of treatment.
ANTIVIRAL RESISTANCE 
Both entecavir and tenofovir are highly potent antivirals with an 
excellent resistance profile, and to which antiviral resistance de-
velops rarely. Nonetheless, the development of antiviral resistance 
is one of the most important factors predicting the success or fail-
ure of CHB treatment. The emergence of antiviral resistance re-
sults in resumption of active viral replication that had been sup-
pressed after the initiation of antiviral therapy, and can impair 
biochemical or histologic improvement.258 Therefore, the preven-
tion, early diagnosis, and management of antiviral resistance may 
significantly affect the long-term prognosis of CHB patients un-
dergoing antiviral therapy.141   
Mechanism of antiviral resistance and definitions
It is estimated that more than 1011 new virions are produced 
daily in a human body with active HBV replication.259 Some of the 
HBV mutants that emerge naturally during active replication are 
selected by the selection pressure exerted by the human immune 
system or antiviral therapy. Those mutants with maximal replica-
tion become predominant during antiviral therapy. Primary antivi-
ral-resistant mutants usually have a low replication capacity, but 
recover to the level of the wild-type virus when compensatory 
mutations appear.260 In addition, a higher fold resistance to antivi-
ral therapy allows increased replication of the mutant virus. A ge-
netic barrier is defined as the number of genetic mutations need-
ed to develop antiviral resistance, with a higher genetic barrier 
indicating a lower risk of resistance.261 The antiviral potency of 
drugs also influences the development of resistance. Drugs with a 
lower antiviral potency or potent antiviral activity have lower risks 
of antiviral resistance, because the former is associated with a 
lower selection pressure and the latter with complete suppression 
of the virus. However, drugs with intermediate potency have an 
increased risk of resistance because residual viremia during treat-
ment may result in selection of mutants with good replication fit-
ness.262 Clinically, the HBV DNA level, history of prior antiviral 
treatment, duration of treatment, serum drug concentration (peak 
and trough), and patient compliance are the most important fac-
tors influencing the development of resistance. Definitions of 
terms associated with antiviral resistance are provided in Table 5.
Mutations conferring resistance to antiviral agents
Antiviral agents for the treatment of HBV infection are classified 
38 http://www.e-cmh.org
Clin Mol Hepatol
Volume_22  Number_1  March 2016
http://dx.doi.org/10.3350/cmh.2016.22.1.18
into two groups: NAs and nucleotide analogues. Cyclopentenes 
(entecavir) and L-nucleoside analogues (lamivudine, telbivudine, 
and clevudine) are NAs, while acyclic phosphonates (adefovir and 
tenofovir) are nucleotide analogues.263 The incidences of resis-
tance to individual antiviral drugs are shown in Table 6.
1. Nucleoside analogues
1)  L-nucleoside analogues (lamivudine, telbivudine, and clevudine)
Mutations at rtM204 are the primary resistance mutations to 
lamivudine, telbivudine, and clevudine.264-267 The rtM204V and 
rtM204I mutations involve the substitution of methionine with 
valine and isoleucine, respectively, at codon 204 of the reverse 
transcriptase gene. Originally these were termed YMDD muta-
tions, but that terminology is no longer recommended.268 rt-
M204V emerges during lamivudine treatment, but rtM204I can 
develop during the administration of lamivudine, telbivudine, or 
clevudine.225,226,269,270 
An rtM204V mutant may commonly accompany rtL180M but 
not rtM204I.271 These mutants are sensitive to adefovir and teno-
fovir, but they exhibit cross-resistance to entecavir and show an 
eightfold decrease in sensitivity. The rtA181T mutation has been 
detected in 5% of lamivudine-resistant patients.272 The mutants 
exhibit cross-resistance to adefovir but remain sensitive to enteca-
vir.272
2) Cyclopentene (entecavir)
Resistance to entecavir develops via a two-hit mechanism. 
rtL180M and rtM204V first develop as background mutations, 
and then additional mutations such as rtT184L/F/A/M/S/I/C/G, 
rtS202G/I/C, or rtM250V/I/L develop as primary resistance muta-
tions to entecavir, resulting in a marked decrease in drug suscep-
tibility.261,273 rtI169T is a compensatory mutation that increases the 
fold resistance of rtT184, rtS202, and rtM250 mutants. Since mul-
tiple genetic mutations are needed to develop high-level resis-
tance to entecavir (high genetic barrier), the resistance rate in 
treatment-naïve subjects is very low. However, a resistance rate 
as high as 51% has been reported after 5 years of treatment in la-
mivudine-refractory subjects.274 
Table 6. Cumulative incidences of development of antiviral resistance according to representative studies.
Antiviral agent
Resistance rate (%)
Year 1 Year 2 Year 3 Year 4 Year 5 Year 6 Year 7 Year 8
Lamivudinea 24 42 53 70 ≥65
Adefovir
in treatment-naïve patients*b 0 3 11 18 29
in lamivudine-resistant patientsc 4.4-18 18.4-25 34.3 52.3 65.6
A defovir + lamivudine 
in lamivudine-resistant patientsd 1 2 4 4
Entecavir
in treatment-naïve patientse 0.2 0.5 1.2 1.2 1.2 1.2
in lamivudine-refractory patientsf 6 15 36 47 51
Tenofovir†g 0 0 0 0 0 0 0 0
Telbivudineh 2.7-4.4 10.8-25.1
Clevudinei  2.3 24.4
*HBeAg-negative patients.
†Emtricitabine was added in patients with detectable HBV DNA after 72 weeks of treatment.
aModified and updated from Lai et al. Clin Infect Dis 2003265 and Lok et al. Gastroenterology 2003.266 
bFrom Hadziyannis et al. Gastroenterology 2006.157
cFrom Lee et al. Hepatology 2006280, Yeon et al. Gut 2006281, and Lee et al. Antivir Ther 2010.216
dFrom Lampertico et al. Gastroenterology 2007.277
e&fTenney et al. Hepatology 2009.274
gLampertico P et al. J Hepatol 2015.283 
hFrom Lai et al. N Engl J Med 2007225 and Liaw et al. Gastroenterology 2009.226
iYoon et al. J Clin Gastroenterol 2011.270 
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2. Nucleotide analogues
1) Adefovir
rtN236T and rtA181V/T are the primary resistance mutations to 
adefovir.157,275 The levels of resistance of rtN236T and rtA181T to 
adefovir are 7- to 10-fold and 2.5- to 5-fold, respectively, com-
pared to the wild-type virus.263,272 rtA181T can be detected in sub-
jects receiving lamivudine monotherapy or combination therapy 
comprising adefovir plus lamivudine.276,277 
2) Tenofovir
Clinically significant resistance mutations to tenofovir have not 
been reported in patients with HBV monoinfection. However, 
rtA194T can decrease the susceptibility to tenofovir 10-fold in the 
presence of rtL180M+rtM204V, according to a case study of a 
patient with HBV and HIV coinfection.278 
Management of antiviral resistance
Prior antiviral resistance predisposes individuals to subsequent vi-
ral mutations and limits the choice of rescue therapies due to the 
presence of cross-resistance.263,279 Although antiviral agents with-
out cross-resistance may be selected, the resistance to the rescue 
therapy is greater than that of treatment-naïve subjects.279-281 
It is therefore critical to initially choose the antiviral agent with 
the lowest resistance rate.  
Appropriate monitoring during treatment is needed to detect vi-
rologic and biochemical breakthroughs as early as possible. Anti-
viral resistance testing is required when a virologic or biochemical 
breakthrough is detected in subjects with good compliance. If ge-
notypic resistance is confirmed, rescue therapy should be initiated 
before the clinical situation deteriorates.282 
[Recommendations]
General principles of antiviral resistance management:
1.  An antiviral resistance test should be performed when viro-
logic breakthrough occurs, especially in cases with good 
compliance. (A1)
2.  Rescue antiviral therapy should be started as soon as possi-
ble upon emergence of resistant variants, especially when 
viral breakthrough is detected and genotypic resistance is 
confirmed. (A1)
MANAGEMENT OF ANTIVIRAL-RESISTANT 
CHB
Management of lamivudine resistance
1. Tenofovir
Tenofovir shows potent antiviral activity against lamivudine-re-
sistant HBV.284-287 In a retrospective study that compared a teno-
fovir monotherapy group with a tenofovir-plus-lamivudine combi-
nation-therapy group for 197 patients (105 naïve patients and 92 
patients resistant to lamivudine), the HBV undetectable rate (HBV 
DNA <20 IU/mL) was not different significantly in the HBeAg-
negative group (94% vs. 96%, respectively) and HBeAg-positive 
group (67% vs. 83%, respectively).285 One comparative study in-
volving lamivudine-resistant CHB patients coinfected with HIV 
found that the HBV DNA level after 48 weeks was <105 cpm in 
100% of patients in the tenofovir group but in only 44% of pa-
tients in the adefovir group, with the difference being statistically 
significant.284 In a study that compared a tenofovir monotherapy 
group with a tenofovir-plus-emtricitabine combination-therapy 
group including 280 patients with lamivudine-resistant HBV, the 
HBV undetectable rate (69 IU/mL) was not significantly different 
(85.8% vs. 83.5%, respectively) and tenofovir-resistant HBV was 
not detected in either group after 96 weeks.287 No prospective 
study has compared tenofovir monotherapy with tenofovir-plus-
lamivudine combination-therapy. However, in a retrospective 
study that compared a tenofovir monotherapy group (n=71) with 
a tenofovir-plus-lamivudine combination-therapy group (n=54) 
among 125 patients with a history of antiviral treatment, the cu-
mulative HBV undetectable rate (<20 IU/mL) differed significantly 
after 3 years (90.7% vs. 96.0%, respectively).286 
2. Adefovir
Adefovir has shown antiviral activity against lamivudine-resis-
tant HBV. The development of resistance to adefovir was signifi-
cantly less frequent in the adefovir-plus-lamivudine combination-
therapy group than in the adefovir-monotherapy group in long-
term studies.288,289 No comparative study of tenofovir monotherapy 
and adefovir plus NA combination therapy has been performed. 
However, combination therapy with lamivudine plus adefovir results 
in a higher adefovir resistance rate (2.2-13.3%) compared to teno-
fovir (0%).290-293 Few studies of combination therapy with adefovir 
plus other NAs such as entecavir, telbivudine, and clevudine in-
stead of lamivudine are available; moreover, the studies reported 
to date have involved small populations. One retrospective study 
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involving 91 lamivudine-resistant CHB patients consisted of ade-
fovir monotherapy (n=29), adefovir and lamivudine combination 
therapy (n=30), adefovir and entecavir 1 mg combination therapy 
(n=32) found that the HBV DNA undetectable rate (<60 IU/mL) 
was not significantly different (48.2% vs. 76.7% vs. 87.5%, re-
spectively) but the adefovir resistance rate differed significantly 
(27.6% vs. 13.3% vs. 0%, respectively) after 24 months.292 In a 
small prospective study that compared an adefovir-plus-telbivu-
dine combination-therapy group (n=21) with an adefovir-mono-
therapy group (n=21), the HBV undetectable rate (<300 copies/
mL) was 38.5% and 0%, respectively, and adefovir resistant virus 
was detected in 9.6% of patients in the adefovir-monotherapy 
group after 96 weeks.294 Two small prospective studies revealed 
that the reduction in HBV load was greater in the adefovir-plus-
telbivudine combination-therapy group than the adefovir-plus-la-
mivudine combination-therapy group.295,296 
3. Entecavir
Entecavir at a dose of 1.0 mg exhibits antiviral activity in lami-
vudine-resistant CHB patients.297,298 In a study of monotherapy 
with 1.0 mg entecavir compared with adefovir-plus-lamivudine 
combination therapy in patients with lamivudine resistance, 
monotherapy showed a significantly higher viral breakthrough 
rate (17.6% vs. 2.0%) but comparable antiviral efficacy.291,299-301 
Two retrospective studies of combination treatment with adefovir 
and entecavir 1 mg in patients with lamivudine resistance re-
vealed a significantly lower viral breakthrough rate (0-2.6%) than 
adefovir combination therapy with another NA or entecavir 1 mg 
monotherapy.292,302 
4. Peginterferon alpha
In a study that compared a group receiving peginterferon alpha 
group for 48 weeks (n=155) with a group receiving adefovir for 
72 weeks (n=80) among patients with compensated liver disease, 
the HBV DNA undetectable rate (<80 IU/mL) was lower (10.6% 
vs. 22.5%), but the HBeAg seroconversion rate was higher (14.8% 
vs. 3.8%) significantly in the peginterferon alpha group.303 There 
was no significant difference in the HBeAg seroconversion rate 
and HBV undetectable rate in another study that compared the 
efficacy of peginterferon alpha between patients with wild-type 
virus and lamivudine-resistant virus.304
[Recommendations]
1.  Switch to tenofovir or combine tenofovir with a nucleoside 
analogue. (A1)
2.  Consider combination of adefovir and a nucleoside ana-
logue if use of tenofovir is contraindicated. (B1)
3.  Stop lamivudine and consider treatment with peginterferon-α 
if the patient has compensated liver function. (B2)
Management of telbivudine resistance
Few data related to telbivudine resistance are available. In a study 
in which telbivudine- resistant patients or viral breakthrough patients 
without resistance (n=68) were treated with adefovir, over 70% of 
patients had an HBV level of ≤300 copies/mL after 12 months.305 
Treatment based on tenofovir could be a therapeutic option, but 
comparative data for telbivudine and lamivudine are insufficient. The 
general principles of management of telbivudine resistance are simi-
lar to those for the management of lamivudine resistance.
[Recommendation]
1.  Follow the recommendations for the management of lami-
vudine-resistant CHB. (B2)
Management of clevudine resistance 
Few data related to clevudine resistance are extant. The general 
principles of treatment of patients with clevudine resistance are 
similar to those of lamivudine resistance.
[Recommendation]
1.  Follow the recommendations for the management of lami-
vudine-resistant CHB. (B2)
Management of adefovir resistance
The HBV mutations rtN236T and rtA181V/T result in primary re-
sistance to adefovir.157,275 rtA181T can also be detected in subjects 
receiving lamivudine monotherapy or combination therapy of ade-
fovir plus lamivudine.272,275-277,306 rtN236T and rtA181T result in 7- 
to 10-fold and 2.5- to 5-fold, respectively, greater resistance to 
adefovir relative to the wild-type virus.263,272 The double mutation 
(rtA181T/V and rtN236T) results in a 5.2- to 18-fold reduction in 
sensitivity to adefovir.272 Patients with persistent drug-resistant 
HBV viremia are more likely to suffer hepatitis flares, disease pro-
gression, and death than those without drug-resistant HBV.307
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The rate of adefovir-resistance is 20% and 29% after 5 years of 
adefovir treatment in HBeAg-positive and HBeAg-negative treat-
ment naïve patients, respectively.157,308 The risk of genotypic resis-
tance to adefovir increases in patients resistant to lamivudine 
compared to treatment-naïve patients. After 48 weeks of adefovir 
treatment, the rate of resistance was 18% and 0% in lamivudine-
resistant and treatment-naïve patients, respectively.280 Moreover, 
the rate of adefovir resistance can reach 22-25% after 2 years of 
treatment in lamivudine-resistant patients.281,309 
1. Lamivudine
In vitro studies showed that the rtN236T mutant remained sen-
sitive to lamivudine, while the rtA181/V mutant exhibited reduced 
susceptibility to lamivudine.272
In adefovir-resistant patients without prior exposure to lamivu-
dine,310 the combination of telbivudine/adefovir and monotherapy 
with entecavir was associated with virologic response rates of 
73.3% and 57.1%, respectively, and HBeAg seroconversion rates 
of only 20% and 0%, respectively.
In patients who developed adefovir resistance in the presence 
of lamivudine resistance, the combination of lamivudine/adefovir 
resulted in a virologic breakthrough rate of 7.3% and primary 
nonresponse rate of 51.2% at 1 year, and a very low virologic re-
sponse rate (HBV DNA <60 IU/mL) of 12.2%.311
2. Entecavir
In vitro studies have shown that HBV with adefovir-mono-resis-
tant mutations may be susceptible to entecavir.272 However, HBV 
with lamivudine-resistance mutations have cross-resistance to en-
tecavir. Thus, in patients resistant to both adefovir and lamivu-
dine, entecavir monotherapy was associated with a suboptimal vi-
rologic response (42%) and high rate of additional resistance to 
entecavir (17%) at 1 year. In these patients, even the combination 
of entecavir/adefovir resulted in a very low virologic response rate 
of 31.1% and 44.7% at 1 and 2 years, respectively.302,312,313
3. Tenofovir
Tenofovir has about 30-fold higher antiviral efficacy than adefo-
vir.314-316 However, in vitro studies show that HBV strains express-
ing the adefovir resistance-associated substitutions, rtA181T/V 
and/or rtN236T, demonstrate reduced susceptibility to tenofovir, 
ranging from 2.9- to 10-fold that of the wild-type virus.276,317-319 
Nonetheless, several studies have suggested that tenofovir diso-
proxil fumarate (TDF) monotherapy is efficacious in patients with 
lamivudine-resistant, entecavir-resistant, adefovir-refractory, and 
adefovir-resistant HBV.287,315,316,320,321 An European trial comparing 
TDF and emtricitabine (FTC) plus TDF in patients with adefovir-re-
fractory CHB demonstrated that the rate of virologic response did 
not differ between TDF and FTC/TDF therapies; 82% vs. 84% at 
3.5 years.315,316 A randomized trial comparing TDF monotherapy 
and TDF/entecavir combination therapy in patients with adefovir-
resistant HBV showed a similar virologic response rate of 62% 
and 63.5%, respectively, at 48 weeks.322 However, in a subgroup 
of patients who had double adefovir-resistance mutations; i.e., 
both rtA181T/V and rtN236T, the decrease in serum HBV DNA 
levels tended to be less in the TDF group than in the TDF/enteca-
vir group (-3.03 log10 IU/mL vs. -3.31 log10 IU/mL, P=0.38). 
[Recommendations]
1.  Switch to tenofovir or combine tenofovir with entecavir. (B1)
2.  Combination therapy with tenofovir and a nucleoside ana-
logue other than entecavir. (B2)
3.  Consider combination of adefovir and a nucleoside ana-
logue if use of tenofovir is contraindicated. (B2)
Management of entecavir resistance
In patients with lamivudine-resistant HBV, the rate of entecavir 
resistance increases to 51% after 5 years of entecavir treatment, 
in contrast to a 1.2% resistance rate in NA-naïve patients.273,274 
The difference is because the entecavir resistance barrier is low-
ered by the initial selection of the lamivudine-resistance HBV mu-
tation, rtM204V/I.323 In vitro studies have shown that susceptibili-
ty to entecavir is decreased by 10-250-fold when one of the 
entecavir resistance-associated substitutions at rtT184, rtS202, or 
rtM250 is present in combination with rtM204V/I, and by >500-
fold when two or more of these mutations are present.273,323
In vitro studies suggest that entecavir-resistant HBV mutants 
are susceptible to adefovir and TDF.324,325 A few cohort studies 
have reported the efficacy of adefovir or TDF in patients with en-
tecavir-resistant HBV.326-329 
1. Adefovir
No randomized trial of adefovir treatment in patients with ente-
cavir resistance has been performed. Adding adefovir to entecavir 
would be more reasonable for reducing adefovir resistance and 
improving the antiviral efficacy.330 Combination therapy of adefo-
vir plus lamivudine could also be considered.331 However, small 
retrospective cohort studies demonstrated that the virologic re-
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sponse rate was 24-51% at 1 or 2 years of treatment with the 
combination of adefovir and entecavir or lamivudine.326-328,332
2. Tenofovir
Tenofovir does not show cross-resistance to entecavir in vitro 
and has excellent potency.333 A Korean multicenter randomized 
trial was performed in HBV patients with entecavir resistance-as-
sociated mutations comparing TDF monotherapy and TDF and en-
tecavir combination therapy for 48 weeks.334 All patients had at 
least one entecavir-resistance mutation: rtT184A/C/F/G/I/L/S, 
rtS202G, and rtM250L/V, in addition to rtM204V/I. At week 48, 
the proportion of patients with HBV DNA <15 IU/mL, the primary 
efficacy endpoint, was not significantly different between the TDF 
and TDF+entecavir groups (71% vs. 73%; P =0.81). Virologic 
breakthrough occurred in one patient on TDF, which was attribut-
ed to poor drug adherence. At week 48, six and three patients in 
the TDF and TDF+entecavir groups, respectively, retained their 
baseline resistance mutations (P >0.99). None developed addi-
tional resistance mutations. Safety profiles were comparable in 
the two groups.
[Recommendations]
1.  Switch to tenofovir or combine tenofovir with entecavir. (B1)
2.  Consider combination of adefovir and a nucleoside ana-
logue if use of tenofovir is contraindicated. (B2)
Management of tenofovir-resistance
No tenofovir-resistant patients have been reported to date. A 
prospective study found no HBV strain resistant to TDF after up to 
8 years of treatment.335 An in vitro study reported that A194T in 
combination with lamivudine resistance mutations, rtL180M and 
rtM204V, might account for TDF resistance in HBV.278 However, 
other in vitro studies have reported inconsistent results.336,337
Management of multiple drug resistance
Multidrug resistance is defined as resistance to two or more 
groups of antiviral drugs; i.e., L-nucleoside (lamivudine, telbivu-
dine, clevudine), cyclopentane (entecavir), or nucleotide analogue 
(adefovir and tenofovir).279,318
Interferon has not been used for the management of patients 
with multidrug-resistant HBV. However, there is also no sugges-
tion that such patients have decreased susceptibility to interferon.
In vitro clonal analyses showed that multidrug-resistance muta-
tions usually reside in the same viral genome,279,318 and replicating 
clones with lamivudine- and adefovir- associated mutations had 
>50-fold reduced susceptibility to combination of lamivudine and 
adefovir.338,339 In fact, a cohort study demonstrated that in pa-
tients with HBV resistant to lamivudine and adefovir, combination 
therapy with these two drugs was not effective and indeed was 
inferior to entecavir monotherapy in terms of suppressing HBV 
DNA.311 However, the response to entecavir monotherapy was not 
optimal. Entecavir was markedly less effective in patients refrac-
tory to both lamivudine and adefovir than in those with lamivu-
dine monoresistance,313 or treatment-naïve patients.273
In patients with multidrug-resistant HBV, a combination of the 
two most potent drugs, TDF and entecavir, would likely prevent 
the emergence of resistance to TDF.340 However, two randomized 
trials in patients with resistance to entecavir and/or adefovir in 
addition to lamivudine resistance showed no difference in virolog-
ic response between TDF monotherapy and TDF and entecavir 
combination therapy, and no emergence of additional resistance 
mutations.322,334 Based on their comparable antiviral efficacy, ex-
tremely low risk of TDF resistance, lower cost, and potentially bet-
ter safety profile, TDF monotherapy would be a reasonable option 
for the treatment of entecavir-resistant patients. 
[Recommendations]
1.  Switch to tenofovir or combine tenofovir with entecavir. (B1)
2.  Consider combining adefovir with a nucleoside analogue if 
use of tenofovir is contraindicated. (B2)
RESPONSE-GUIDED THERAPY DURING ORAL 
ANTIVIRAL DRUG TREATMENT FOR CHB
Once antiviral-resistant HBV mutants have been selected, they 
are persistently archived (retained in the virus population) in ccc-
DNA in the nucleus of infected cells, even if treatment is stopped, 
which can limit future therapeutic options.341,342 Preventing the 
development of resistance is important to ensure long-term thera-
peutic efficacy. Persistence of viral replication during antiviral 
treatment is associated with the emergence of drug resis-
tance.225,343,344 Therefore, evaluation of the treatment response 
using sensitive PCR assays to measure serum HBV DNA levels ev-
ery 3-6 months is recommended.
The response patterns of oral antivirals during treatment are 
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classified as complete response, partial response and primary 
non-response. Complete response is defined as undetectable se-
rum HBV DNA by PCR during treatment. Partial virologic response 
is defined as detectable serum HBV DNA with a more than 2 log10 
IU/mL reduction in HBV DNA level from baseline.345 A primary 
non-response is defined as a reduction in the serum HBV DNA 
level of less than 2 log10 IU/mL at week 24.
35 Virologic break-
through is defined as an increase in serum HBV DNA level of more 
than 1 log10 IU/mL from nadir. Although virologic breakthrough is 
generally associated with emergence of resistance mutations, up 
to 30% of the cases of virologic breakthrough in clinical trials are 
related to medication noncompliance.346 Therefore, compliance 
should be checked in all patients with a sub-optimal response. 
In patients with a complete virologic response, treatment should 
be continued until the endpoint is achieved, which should be 
evaluated by measuring the serum HBV DNA level every 3–6 
months.117,347 Primary non-response is very rare in oral antiviral 
therapy, with the exception of adefovir. Therefore, few studies of 
primary non-response patients have been performed. In patients 
with primary non-response with good compliance, switching to a 
drug with a high genetic barrier is indicated if the patient is taking 
a drug with a low genetic barrier, due to the possibility of imma-
nent resistance.117,347 However, a recent study of entecavir for 
treatment-naïve CHB reported a primary non-response rate of 1.3-
1.7%, and all patients achieved a virologic response after continu-
ing entecavir therapy during follow up.348,349 Therefore, if the pa-
tient is taking a drug with a high genetic barrier, such as entecavir 
or tenofovir, treatment could either be switched to another high-
genetic-barrier drug or be continued using the same high genetic 
barrier drug with monitoring for virologic response at 3-6-month 
intervals in patients with primary non-response.
The rate of emergence of lamivudine or telbivudine-resistant 
HBV was directly proportional to the HBV DNA level after 24 
weeks of treatment.225,343,344 Yuen and colleagues found that 
these rates were 8%, 13%, 32%, and 64% for patients with 24-
week HBV DNA levels of <200, 3 log10, 4 log10, and 4 log10 or 
higher, respectively, after a median follow-up of 29 months.344 Al-
though few studies on this issue have been conducted, a partial 
response should be evaluated at 6 months after therapy and 
switching to a drug with a higher genetic barrier should be con-
sidered if lamivudine or telbivudine is used.117,347 A prospective 
study of switching to entecavir 1 mg in patients with a partial re-
sponse to lamivudine reported a virologic response rate of 67.6% 
and a resistance rate of 3% at 96 weeks.350 However, a history of 
exposure to lamivudine is associated with a high rate of emer-
gence of entecavir resistance during entecavir therapy.351 There-
fore, switching to entecavir should be considered carefully. The 
response to tenofovir monotherapy was influenced by neither a 
previous history of lamivudine treatment nor resistance.287,333,352-354 
The incidences of adefovir resistance at 114 weeks of adefovir 
therapy in patients with an HBV DNA level of less than 1,000 cop-
ies/mL, 103-106 copies/mL or more than 106 copies/mL at 48 
weeks of adefovir therapy were 4%, 26% and 67%, respective-
ly.355 A partial virologic response to adefovir should be evaluated 
at 12 months after adefovir therapy and switching or adding anti-
virals is recommended for patients with a partial virologic re-
sponse.345 Although a prospective controlled study reported that 
the virologic response rates were 81% and 88% after 12 months 
of therapy with adding lamivudine or telbivudine in patients with 
a partial virologic response to adefovir at 48 weeks,356 these com-
bination therapies have a substantial risk of emergence of resis-
tance during long-term treatment.293 Switching to entecavir 1.0 
mg needs to be done with upmost caution since the incidence of 
entecavir resistance was as high as 25.7% in patients with adefo-
vir resistance.357 In a prospective controlled study of treatment-
naïve CHB patients, the virologic response rate during adefovir 
therapy at 48 weeks was 63% but increased to 90% after switch-
ing to tenofovir for a further 48 weeks.314 Tenofovir is an effective 
alternative for patients with a suboptimal response to adefovir 
and adefovir resistance mutations,316 and no report of tenofovir 
resistance has been published.
Partial virologic response to entecavir and tenofovir (which have 
a high genetic barrier) should be evaluated at 12 months after 
therapy due to the high potency and low incidence of resis-
tance.345 Although some studies suggested that a partial virologic 
response to entecavir could be defined as a serum HBV DNA level 
of 1,000 IU/mL or 35 IU/mL at 12 months after therapy,246,358 it is 
generally defined as detectability of HBV DNA by PCR. The inci-
dence of a partial virologic response to entecavir therapy has 
been reported to be 10% to 28% and that of a virologic response 
to maintenance entecavir therapy after a partial virologic response 
have been reported to be 45% to 95%.349,358-361 Although switching 
therapy to tenofovir in 14 patients with a decline in HBV DNA level 
of less than 1 log10 during more than 6 months of entecavir therapy 
achieved a virologic response in all patients during a mean of 50 
weeks of tenofovir therapy,362 further studies are needed to deter-
mine the optimal treatment strategy for patients with a partial viro-
logic response to entecavir. Although a partial virologic response 
has been found in patients with a high genetic barrier, continuing 
the antiviral agent, especially in cases with a continuous decrease 
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in HBV DNA level, could be recommended as the incidence of resis-
tance during long-term treatment is low.345 However, switching to 
another high genetic barrier antiviral is another option. 
 [Recommendation]
1.  In patients with a complete virologic response, treatment 
should be continued until the treatment endpoint is 
achieved, and monitored by measuring the serum HBV DNA 
level every 3–6 months. (B1)
2.  Drug compliance should be checked thoroughly in patients 
with a partial virologic response or primary non-response. 
For patients treated with a drug with a low genetic barrier, 
treatment should be switched to a drug with a higher ge-
netic barrier. (B1) For patients treated with a drug with a 
high genetic barrier, treatment could either be switched to 
another drug with a high genetic barrier or be continued 
with monitoring for a virologic response at 3-6-months in-
tervals. (C1)
3.  In the event of viral breakthrough, rescue therapy should 
be implemented according to the genotypic resistance 
profile. (A1)
4.  The treatment strategy should follow the recommenda-
tions for treating drug-resistant HBV when genotypic resis-
tant mutations are identified. (A1)
TREATMENT OF SPECIAL POPULATIONS
Acute hepatitis B
Acute hepatitis B resolves spontaneously and does not progress 
to the chronic stage in more than 95% of patients, so antiviral 
therapy is generally not recommended.363,364 Early initiation of an-
tiviral therapy has been reported to interfere with the normal pro-
tective immune response and suppresses production of neutraliz-
ing antibodies against hepatitis virus, increasing the risk of 
chronic hepatitis.365 However, acute hepatitis B infection seldom 
progresses to serious hepatitis and may lead to hepatic failure.364 
According to a randomized controlled trial in 71 patients with se-
vere acute hepatitis B, HBV DNA levels were significantly lower in 
the lamivudine-treated group (n=31, 3.7 log10 copies/mL) com-
pared with the control group (n=40, 4.2 log10 copies/mL) after 4 
weeks. However, the rate of HBsAg loss after 12 months was sim-
ilar in the two groups (93.5% in the lamivudine group and 96.7% 
in the placebo group).366 In this study, the rate of development of 
protective anti-HBs after 1 year was 67.7% in the lamivudine 
group and 85% in the placebo group; the difference was not sig-
nificant. A recent, small, prospective, controlled study also reported 
no significant benefit of lamivudine in severe acute hepatitis B.367 In 
contrast, Tillman et al. reported that lamivudine is safe in patients 
with severe acute or fulminant hepatitis B, leading to rapid recovery 
with the potential to prevent liver failure and liver transplantation 
when administered sufficiently early.368 However, only a few case 
reports of antiviral agents as treatment for acute hepatitis B other 
than lamivudine have been published to date.369-371
[Recommendation]
1. For patients with acute hepatitis B, oral antiviral therapy 
might be considered in cases of persistent serious hepatitis 
or acute liver failure. (C1)
Liver transplant patients
In the past, severe liver damage and a low survival rate due to 
HBV recurrence after liver transplantation in HBV-related liver dis-
order patients were major problems.372-379 However, in an exten-
sive cohort study of 372 patients who received liver transplants in 
the early 1990s and were positive for HBsAg, the study group 
treated with HBIG therapy for more than 6 months showed a sig-
nificantly lower rate of hepatitis B recurrence than the group 
treated with HBIG therapy for less than 6 months or those who 
were not treated. The study group also had a higher long-term 
survival rate than the other groups.380 Since then, several studies 
have reported hepatitis B recurrence rates ranging from 16% to 
35% after liver transplantation in groups receiving high-dose 
HBIG (10,000 IU) therapy.381-383 
Lamivudine and HBIG combination therapy reduces the rate of 
HBV recurrence to less than 10% after 1–2 years and is superior 
to high-dose HBIG therapy with respect to cost and effective-
ness.384-387 In a meta-analysis of six independent studies, lamivu-
dine and HBIG combination therapy was found to reduce the rates 
of HBV recurrence and death 12-fold compared with HBIG therapy 
alone.388,389 A meta-analysis of 46 studies in which 2,161 HBV-in-
fected patients received liver transplants found that adefovir and 
HBIG combination therapy significantly reduced the rate of hepa-
titis B recurrence to 2% compared to 6% with lamivudine and 
HBIG combination therapy.390 
In patients who received lamivudine monotherapy without 
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HBIG, the hepatitis B recurrence rate after 4 years of liver trans-
plantation was ~40%.391,392 In contrast, a study of lamivudine and 
adefovir combination therapy reported no recurrence in CHB pa-
tients during the 22-month observation period.393 In patients who 
received entecavir monotherapy without HBIG,394,395 the rate of 
HBsAg loss was 88-91% and negative viremia was maintained in 
more than 98% during a 26-53-month follow up; moreover, the 
rate of HBV recurrence was lower than that with lamivudine 
monotherapy.395
In a meta-analysis of 19 studies, lamivudine or adefovir with 
HBIG significantly reduced HBV recurrence compared to mono-
therapy with either lamivudine or adefovir.396 However, in a meta-
analysis of 17 studies with 519 patients, those treated with lami-
vudine and HBIG (6.1%) combination therapy showed a rate of 
HBV recurrence comparable to that of those treated with either 
entecavir or tenofovir monotherapy (3.9%, P =0.52), and signifi-
cantly higher than that of those treated with the combination of 
HBIG and either entecavir or tenofovir therapy (1%, P<0.001).397 
To date, few studies regarding entecavir or tenofovir monotherapy 
for the prevention of HBV recurrence after liver transplantation 
have been reported. Therefore, the combination of an antiviral 
and HBIG is recommended to prevent HBV recurrence after liver 
transplantation. 
To reduce the cost of HBIG, studies of low-dose HBIG in combi-
nation with an antiviral or conversion to antiviral monotherapy af-
ter short-term HBIG combination therapy have been performed. In 
a study of 147 patients who received liver transplants, Gane et al. 
showed that lamivudine and low-dose HBIG (400–800 IU) combi-
nation therapy effectively suppressed the recurrence of hepatitis B 
at a moderate cost, as the 5-year recurrence rate of hepatitis B 
was 4%.398 Furthermore, patients with HBV DNA levels of less 
than 2.5 pg/mL before liver transplant and treated with lamivu-
dine and HBIG (2,000 IU) combination therapy for 1 month after 
liver transplant were randomly assigned to either a combination 
therapy maintaining group or lamivudine monotherapy group. The 
rates of HBV recurrence and patient survival did not differ be-
tween the two groups.399 Two other retrospective studies reported 
no recurrence of HBV when lamivudine and HBIG combination 
therapy or HBIG therapy alone for 2 years after liver transplanta-
tion was replaced with lamivudine monotherapy.400,401 In a recent 
study by Angus et al., lamivudine and low-dose HBIG (800 IU) 
combination therapy was continued for at least 12 months after 
liver transplantation. The group in which HBIG was replaced by 
adefovir and the group in which HBIG was continuously adminis-
tered showed similar rates of hepatitis B recurrence.402 Lamivudine 
and adefovir combination therapy with initial short-term low-dose 
HBIG (400-800 IU) did not show HBV recurrence during the 
57-month follow-up period.393 
Few studies with a small number of patients have evaluated en-
tecavir- or tenofovir-based therapy to reduce HBIG usage. The HBV 
recurrence rate was reported to be 10% (1/10)403 and 0% (0/11)404 
when combination entecavir and HBIG therapy was converted to 
entecavir monotherapy; there was no HBV recurrence after convert-
ing to tenofovir monotherapy in 9 patients403 and 17 patients.404 
The rates of recurrence were 5.9% (1/17)405 and 4.8% (1/21)406 in a 
study of conversion to tenofovir and emtricitabine (Truvada®); how-
ever, HBIG withdrawal had an economic benefit. Although these 
studies suggested the possibility of reducing the dose and duration 
of HBIG treatment, further work is needed to determine the opti-
mal duration, amount and type of antiviral treatment.
If hepatitis B recurs after preventive HBIG therapy following liver 
transplantation, lamivudine therapy could effectively inhibit the 
virus. However, it has been reported that long-term lamivudine 
therapy is associated with a resistance rate of >50% after 3 
years.407-409 Such lamivudine resistance causes inflammatory 
changes and hepatic fibrosis in the transplanted liver; indeed, 
death following hepatic failure is possible in severe cases.408,410,411
A few studies have reported the effects of tenofovir and enteca-
vir on hepatitis B recurrence after liver transplantation; however, 
further research is required.412 Several studies have reported rela-
tively good efficacy of lamivudine and adefovir in patients with 
recurrent hepatitis B who exhibit lamivudine resistance after liver 
transplantation. The most extensive study administered the com-
bination therapy to 241 patients with recurrent hepatitis B. The 
rate of reduction in HBV DNA was 65%, whereas the rate of lami-
vudine resistance at 96 weeks after the initiation of therapy was 
2%.413 Although these studies were conducted for a short period 
in small groups, it was recently reported that tenofovir is effective 
against mutants with lamivudine resistance.411,414 However, a high 
rate of emergence of entecavir resistance has been reported when 
entecavir is administered as a rescue therapy to patients with la-
mivudine resistance.274 Therefore, entecavir is not recommended 
in patients with lamivudine resistance after liver transplantation.
If HBsAg seronegative patients receive liver transplants from 
positive anti-HBc donors, ~50% will develop new hepatitis B.415 
When HBIG therapy was administered to these patients after liver 
transplantation, hepatitis B occurred in >20%. However, when la-
mivudine therapy was applied, hepatitis B developed only in 
2–3% of patients. Nevertheless, lamivudine and HBIG combina-
tion therapy had no additional preventive effects compared to la-
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mivudine therapy alone.415-417 The protective effect against HBV 
recurrence was similar between lamivudine and entecavir or teno-
fovir.418 Lamivudine was more cost-effective than entecavir or te-
nofovir according to a Markov model.419 
[Recommendation] 
1.  Pre-transplant therapy with a NA is recommended for all 
HBsAg-positive patients undergoing liver transplantation 
to achieve the lowest possible level of HBV DNA before 
transplantation. (A1)
2.  Antiviral therapy before liver transplantation should com-
ply with the guidelines for chronic hepatitis B therapy. (B1) 
3.  Therapy with a NA and HBIG should be administered for the 
lifetime of the patient to prevent recurrence of hepatitis B 
after liver transplantation, until more evidence regarding 
alternative treatment regimens is accumulated. (B1) If se-
rum HBV DNA becomes negative before the liver trans-
plant, withdrawal of HBIG may be considered in certain pa-
tients after long-term monitoring. (B1)
4.  In case of HBV recurrence after liver transplantation, a po-
tent NA with a high barrier to resistance is recommended. 
(B1) Upon emergence of drug-resistant variants, the CHB 
treatment guidelines should be followed. (B1) 
5.  When an HBsAg-negative recipient receives an HBsAg-neg-
ative but anti-HBc-positive graft, the recipient should take 
oral antivirals indefinitely. (B1)
Immunosuppression and chemotherapy
The clinical course of individual patients with chronic hepatitis B 
is affected by the interaction between the virus and the host im-
mune system. Impaired host immunity due to chemotherapy or 
immunosuppressive treatment increases the risk of HBV reactiva-
tion.420 Previously, HBV reactivation referred to the reappearance 
of necroinflammatory disorders in patients with either inactive 
CHB or with resolved hepatitis,421 and was commonly defined as 
an increase in the serum HBV DNA of >10-fold the baseline level 
or an absolute level of >108 IU/mL together with elevated serum 
ALT (higher than 3× ULN or an absolute increase of >100 IU/
L).422,423 However, most studies of HBV reactivation used their own 
definition of HBV reactivation, and so the exact incidence of HBV 
reactivation during immunosuppressive therapy or chemotherapy 
was unclear. In addition, several terms such as “preventive”, “pro-
phylactic” and “preemptive” were used but not clearly defined, 
which resulted in confusion in scientific communications. In this 
guideline, “prophylactic” therapy means starting antiviral therapy 
simultaneously with initiation of immunosuppressive therapy or 
chemotherapy. Meanwhile, “preemptive” therapy means deferring 
antiviral therapy until the HBV DNA level increases. We prefer the 
term “preventive” therapy, which means not only starting antiviral 
therapy upon initiation of immunosuppressive therapy or chemo-
therapy but also deferring antiviral therapy until the HBV DNA 
level increases. 
Two definitions of HBV reactivation are in use.424 One is exacer-
bation of chronic HBV infection, and the other is relapse of past 
HBV infection. Exacerbation of chronic HBV infection is defined 
≥2log10 increase of HBV DNA level from the baseline level or a 
new appearance of HBV DNA to a level of ≥100 IU/mL. Relapse of 
past HBV infection is defined among HBsAg negative, IgG anti-
HBc positive and HBV DNA negative patients as reappearance of 
HBsAg or detectable HBV DNA. The diagnosis of HBV reactivation 
requires the exclusion of other conditions such as chemotherapy-
related hepatic injury, hepatic metastases, and other types of viral 
hepatitis. The reactivation rate has been reported to be 20-50%, 
although the ranges varied among studies. Many patients with 
HBV reactivation are asymptomatic, but the clinical course varies 
widely from jaundice to decompensation or even death.422,425-427 In 
typical cases, HBV DNA appears in the serum during immunosup-
pressive treatment, followed by elevation of ALT after treatment 
cessation. If HBV reactivation occurs during chemotherapy, treat-
ment disruption or premature termination may adversely affect 
the outcome of chemotherapy.428-430 Predictive factors for HBV re-
activation include the pretreatment HBV DNA level, HBeAg posi-
tivity, cccDNA in hepatocytes and PC/BCP mutation as viral fac-
tors, type of malignancy, male and young age as host factors, and 
type or intensity of immunosuppression or chemotherapy and he-
matopoietic stem cell or organ transplantation as environmental 
therapeutic factors.431 
The reported reactivation rate in lymphoma patients ranges 
from 24% to 67%, possibly due to intense chemotherapeutic regi-
mens against lymphoma and higher HBsAg positivity rates in 
these patients.426,432-434 Rituximab, which is commonly adminis-
tered with corticosteroid for lymphoma, further increases the risk 
of HBV reactivation.435,436 One retrospective study reported a 
27.8% (45/162) HBV reactivation rate among HBsAg-positive lym-
phoma patients, with a lower rate of HBV reactivation in the pre-
ventive antiviral therapy group compared to the non-preventive 
antiviral therapy group (22.9% [32/140] vs. 59.1% [13/22]; 
P<0.001).437 In this study, entecavir reduced the rate of HBV reac-
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tivation to a greater degree than lamivudine (6.3% vs. 39.3%; 
P<0.05). In HBsAg negative/anti-HBc positive patients, the rate of 
HBV reactivation was 2.4% in this retrospective study. Another 
prospective study of HBsAg negative/anti-HBc-positive lymphoma 
patients reported a higher rate of HBV reactivation and hepatitis 
aggravation (10.4 and 6.4 per 100 person-years, respectively) 
during rituximab plus cyclophosphamide, doxorubicin, vincristine, 
and prednisone (R-CHOP) chemotherapy.438 In this study, close 
monitoring of HBsAg and HBV DNA with immediate antiviral ther-
apy usually overcame the complications of HBV reactivation; how-
ever, some cases showed marked aggravation and progression of 
severe hepatitis, which was associated with reappearance of HB-
sAg compared to reappearance of HBV DNA without HBsAg 
(100% vs. 28%). A rituximab-containing regimen increased the 
risk of HBV reactivation among HBsAg-positive and HBsAg-nega-
tive/anti-HBc-positive lymphoma patients (relative risk 2.14, 95% 
CI 1.42–3.22, P=0.0003), especially in HBsAg-negative/anti-HBc-
positive lymphoma patients (relative risk 5.52).439 Preventive anti-
viral therapy in lymphoma reduced the rate of HBV reactivation 
significantly compared to a non-preventive group (13.3% vs. 
60%).440 Pretreatment screening for HBsAg and anti-HBc before 
R-CHOP chemotherapy in lymphoma and preventive antiviral ther-
apy enhanced survival and cost-effectiveness by reducing the rate 
of HBV reactivation.441 
The risk of reactivation is also elevated when high-intensity che-
motherapy is applied prior to hematopoietic stem-cell transplanta-
tion in hematologic malignancies.442,443 Similarly, preventive anti-
viral therapy with lamivudine or entecavir reduced the rate of HBV 
reactivation.444 Although the reactivation rate was 14-21% in sol-
id tumors, higher rates of 41-70% were reported in breast cancer, 
possibly related to the use of high-dose chemotherapy with an-
thracycline agents and steroids.430,445,446 The rate of HBV reactiva-
tion during transcatheter arterial chemoembolization (TACE) as a 
therapeutic option for HCC was 4-40%.447-450 Preventive lamivu-
dine therapy compared to non-preventive group reduced the rates 
of HBV reactivation (2.8% vs. 40.5%), hepatitis aggravation 
(2.8% vs. 29.7%) and hepatic failure (0% vs. 8.1%) significant-
ly.448 Preventive antiviral therapy can be considered in cases un-
dergoing TACE for HCC treatment to reduce HBV reactivation; 
however, the rates of HBV reactivation during TACE differed ac-
cording to procedure method, interval, frequency and the TACE 
agents.447,448,451 Therefore, further studies are required to elucidate 
the criteria for preventive antiviral therapy in TACE. Sorafenib, 
which was approved for advanced HCC, seems not to cause HBV 
reactivation452 but this should be confirmed in further investiga-
tions. Steroids can suppress the host immune system but also in-
duce HBV replication directly, which increases the risk of HBV re-
activation. Other risk factors for reactivation include the use of 
anti-TNF agents for inflammatory bowel diseases or rheumatolog-
ic diseases (e.g., infliximab, etanercept, and adalimumab), the 
HBV genotype or specific mutations in the HBV genome, and re-
covery from neutropenia.453-462 The rate of HBV reactivation was 
12.3% among HBsAg-positive patients receiving an anti-TNFα 
antibody or disease-modifying antirheumatic drug (DMARD), 
which are used in rheumatologic diseases.463 Other study reported 
a rate of HBV reactivation of 39% among HBsAg-positive patients 
and 5% among isolated anti-HBc-positive patients receiving anti-
TNFα antibody therapy. Preventive antiviral therapy decreased the 
rate of HBV reactivation significantly (23% vs. 62%, P=0.003).464 
Because HBV reactivation is associated with the risk of hepatic 
failure and death, prevention is of utmost importance. This neces-
sitates screening for HBsAg and IgG anti-HBc . Vaccination should 
be considered if there is no evidence of (past) HBV infection (i.e., 
negative for both HBsAg and IgG anti-HBc). Preventive antiviral 
therapy is recommended in HBsAg-positive patients regardless of 
the serum HBV DNA level.455 Preventive lamivudine therapy has 
significantly reduced the rates of HBV reactivation, hepatic failure, 
and mortality in randomized controlled studies of lymphoma pa-
tients in Hong Kong and Taiwan.433,443,465,466 Therefore, it is recom-
mended that preventive antiviral therapy be started simultaneous-
ly with the initiation of chemotherapy rather than deferring until 
the HBV DNA level increases, and should be maintained for cer-
tain period after the termination of chemotherapy (e.g., at least 6 
months).466,467 However, evidence that can be used to determine 
the duration of preventive antiviral therapy remains limited. Ele-
vated risk of reactivation was reported with cessation of preven-
tive lamivudine therapy at 3 months following the termination of 
chemotherapy, especially in cases with a high HBV DNA level be-
fore chemotherapy (≥2,000 IU/mL).468 Therefore, the duration of 
preventive antiviral therapy could be determined based upon 
treatment guidelines for CHB if the pre-treatment HBV DNA level 
is high. In contrast, attention should be paid to reports of reacti-
vation after more than 6 months irrespective of the pre-treatment 
HBV DNA level. Although there is limited information about the 
efficacy of preventive treatment with other antiviral agents—such 
as adefovir, telbivudine, clevudine, entecavir, and tenofovir—
these agents could be administered for preventive purpose con-
sidering their mechanisms of action and therapeutic results. Since 
resistance was reported in preventive lamivudine therapy, other 
antiviral agents with lower resistance rates should be considered 
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in cases with prolonged treatment (e.g., >1 year).433 A retrospec-
tive study reported that the risks of hepatitis and chemotherapy 
disruption due to HBV reactivation in lymphoma patients were 
lower for entecavir than for lamivudine.469 However, data on the 
relative efficacy and cost-effectiveness of antiviral agents are 
scarce. Prospective studies to determine the appropriate antiviral 
agents and optimal treatment duration in various types of malig-
nancy are needed, as most previous studies involved only lym-
phoma patients. If cost is ignored, entecavir and tenofovir are ap-
propriate choices based on their potency and resistance rate. 
Interferon-α is contraindicated for preventive use due to its bone 
marrow suppression and exacerbation of underlying hepatitis.
In some cases, HBV reactivation occurs not only in HBsAg-posi-
tive patients but also in IgG anti-HBc-positive patients without 
HBsAg.470 The latter cases correspond to either occult HBV infec-
tion in which HBV DNA is detected in the hepatocytes or even in 
the serum, or reverse seroconversion (seroreversion) of HBsAg in 
which HBV replication resumes after immunosuppression with re-
appearance of HBsAg.422,471,472 The rate of HBV reactivation is high-
er in patients with isolated anti-HBc than in patients with both anti-
HBc and anti-HBs.473 IgG anti-HBc-positive patients (HBsAg-
negative) have a risk of HBV reactivation irrespective of anti-HBs, 
but a uniform treatment recommendation cannot be provided be-
cause the effects of the type of malignancy or immunosuppressive/
chemotherapeutic agents used on the reactivation risk are unclear. 
However, preventive therapy should be started if serum HBV DNA 
is positive in high-risk groups such as patients with lymphoma un-
der a rituximab-containing regimen or those with leukemia who 
undergo hematopoietic stem cell transplantation; preventive treat-
ment may be started together with immunosuppressive/chemo-
therapy or determined with periodic monitoring (e.g., every 1-2 
months) of the HBV DNA level in patients with no detectable se-
rum HBV DNA at baseline.
[Recommendation]
1.  It is recommended to screen for HBsAg and IgG anti-HBc 
prior to initiation of immunosuppressive treatment or che-
motherapy. If either is positive, serum HBV DNA should be 
tested. (A1)
2.  Patients without evidence of HBV infection should be vacci-
nated. (B1)
3.  Consider preventive antiviral therapy simultaneously with 
the initiation of immunosuppressive treatment/chemother-
apy if HBsAg or HBV DNA is positive. (A1) Although selec-
tion of a NA requires consideration of the serum HBV DNA 
level, the intensity and duration of immunosuppressive 
treatment/chemotherapy and the cost, entecavir or tenofo-
vir can be preferentially considered if the baseline HBV DNA 
level is high or long-term treatment is anticipated. (C1)
4. If IgG anti-HBc is positive without HBsAg or HBV DNA, irre-
spective of anti-HBs, serum HBV and HBsAg should be test-
ed regularly and preventive antiviral therapy should be 
considered if either reappears during immunosuppressive 
treatment/chemotherapy. (A1) Preventive antiviral therapy 
in patients with isolated anti-HBc can be initiated in high-
risk groups such as patients with lymphoma under a ritux-
imab-containing regimen or those with leukemia who un-
dergo hematopoietic stem cell transplantation. (B2)
5.  Serum HBV DNA should be monitored periodically during 
and after preventive antiviral therapy. (A1)
6.  Preventive antiviral therapy should be maintained for at 
least 6 months after the termination of immunosuppressive 
treatment/chemotherapy. (C1)
Patients with chronic kidney disease and under 
dialysis
Patients under dialysis are relatively prone to being exposed to 
HBV infection, which might exert a negative influence on their 
long-term prognosis. Exacerbation of hepatitis B is of particular 
importance for immunosuppression after renal transplantation.474 
Fortunately, the incidence of HBV infection in dialysis patients has 
decreased due to surveillance of blood products, enhanced infec-
tion control, and widespread use of erythropoietin. The preva-
lence of HBV infection based on HBsAg positivity in this popula-
tion is 0-6.6% in Western countries, and ~5% in Korea in recent 
reports.475-477 The prevalence of occult HBV infection was higher 
than the HBsAg-positivity rate in one report,478 but this was not 
the case in Korea.479 The standard precautions to avoid nosocomi-
al transmission are of the highest priority for preventing new HBV 
infections in dialysis patients.480 Vaccination against HBV is widely 
recommended in these patients; the efficacy is higher with earlier 
vaccination because the antibody production rate is 50-60% 
compared with ~90% in the general population, and decreases 
as residual renal function declines.481-483 Data on antiviral treat-
ment in dialysis patients are insufficient. Although a randomized 
controlled study of interferon-α in HBV-infected patients with glo-
merulonephritis has been performed,484 it is difficult to recom-
mend its use due to the increased adverse events in this popula-
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tion due to pharmacodynamic changes.485,486 Several small studies 
have reported the effectiveness of lamivudine.487-489 Resistance to 
lamivudine was 39% at 16.5 months of treatment, which was 
similar to the rate in patients with normal renal function.490 Ente-
cavir or tenofovir may be preferentially used, given their potency 
and resistance profile in patients with normal renal function.35 
Careful dose adjustment is required for adefovir and tenofovir due 
to their potential nephrotoxicity in patients with residual renal 
function.491-494 Tenofovir is less nephrotoxic than adefovir. Two of 
426 patients with chronic hepatitis B who underwent tenofovir 
therapy for 144 weeks showed elevation of serum creatinine to 
>0.5 mg/dL compared to baseline with no reduction in glomerular 
filtration rate to <50 mL/min.495 
[Recommendation]
1.  Vaccination is recommended for patients under dialysis 
negative for HBsAg and anti-HBs. (A1)
2.  Oral NAs such as entecavir and tenofovir are preferable to 
interferon therapy in patients under dialysis. (B1) NAs 
should be dose-adjusted according to residual renal func-
tion. (A1)
CO-INFECTION WITH OTHER VIRUSES
HCV Co-infection
In patients with CHB the anti-HCV antibody positivity rate var-
ies from 0.1% to 22%, depending on the region496-499 with it be-
ing very low in Korea (0.1%).497 Patients with HBV/HCV co-infec-
tion have an increased risk of severe or fulminant infection, and 
high incidences of cirrhosis and HCC.500-503 The scarcity of data 
makes it impossible to recommend a treatment for HBV/HCV co-
infection.504-506 However, it is necessary to determine which virus 
is dominant by means of serologic or virology tests. If HCV RNA is 
positive with a low or undetectable serum HBV DNA level, HCV 
infection should be considered dominant and the patient treated 
as for HCV monoinfection. Combination therapy of pegIFN-α-2a 
plus ribavirin is equally effective in patients with HCV monoinfec-
tion and HBV/HCV co-infection.507,508 HBV treatment should be 
added when HBV reactivates, which can reportedly occur during 
or after combination therapy of pegIFN-α plus ribavirin for HCV.509 
The role of direct-acting agents (DAAs) in HBV/HCV co-infection 
needs to be elucidated.
[Recommendations]
1.  After confirming the dominant cause of liver disease in 
HBV/HCV coinfection, treatment following the same strate-
gy as that for the dominant virus is recommended. (B1)
2.  HBV treatment should be initiated when HBV proliferation 
is identified during or after treatment for HCV. (B1)
HDV Co-infection
It is estimated that ~20 million people are infected with HDV 
worldwide.510 HDV infection is prevalent in Mediterranean coun-
tries, the Middle East, central Africa, and South America.511 The 
HDV co-infection rate in CHB patients has been reported to be 
0-3.6% in Korea.512-514 The incidences of cirrhosis and HCC are 
higher in patients with HBV/HDV coinfection than in those with 
HBV monoinfection.515,516 
HDV infection can be diagnosed by detecting anti-HDV antibody 
or HDV RNA in the serum or by detecting HDV antigen in liver tis-
sue by immunohistochemistry. The treatment goals are to inhibit 
HDV replication, normalize ALT, and improve histology findings. 
IFN-α (conventional or pegylated) is the only drug that can inhibit 
HDV replication.517-521 The biochemical, virologic, and histologic 
responses to high-dose IFN-α therapy (9 MU, three times per 
week) were better than those to the conventional dose of IFN-α (3 
MU, three times per week), with the high-dose therapy producing 
an HDV RNA negativity rate of 43% at 6 months after the end of 
48 weeks of treatment.520 PegIFN-α showed HDV RNA negativity 
rates of 17-43% at 6 months after the end of 48 or 72 weeks of 
treatment.517,521,522 No head-to-head comparison trial between 
high-dose IFN-α and pegIFN-α therapies has been performed and 
hence either pegIFN-α or high-dose IFN-α therapy for longer than 
1 year is recommended for patients with HBV/HDV co-infection.523 
The treatment response can be evaluated by measuring the serum 
HDV RNA level at week 24. Both lamivudine and adefovir were 
found to be ineffective in terms of inhibiting HDV replication.524,525 
Combination therapy of lamivudine plus IFN-α was not superior 
to IFN-α monotherapy,526 and adefovir plus pegIFN-α therapy did 
not improve the response rate compared to pegIFN-α monothera-
py.525 In addition, the rates of HDV DNA negativity at 24 weeks 
after therapy with the combination of adefovir plus pegIFN-α or 
pegIFN-α monotherapy for 48 weeks were superior to those fol-
lowing adefovir monotherapy for 48 weeks (26%, 31% and 0%, 
respectively).527
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[Recommendation]
1.  CHB patients with HDV co-infection should be treated with 
peginterferon-α or high dose interferon-α (9 MU, three 
times per week) for >1 year. (B1)
HIV Co-infection
The incidences of cirrhosis and HCC are reportedly higher in pa-
tients with HBV/HIV coinfection than in those with HBV monoin-
fection.528,529 HBV should be treated in HBV/HIV-coinfected pa-
tients who exhibit ALT elevation due to HBV. Before such 
treatment it is necessary to determine whether treatment for HIV 
is also required.530 Patients who are not indicated for HAART 
should receive the standard treatment for CHB. In such cases anti-
viral agents (e.g., IFN, adefovir, or telbivudine) that do not affect 
HIV proliferation should be selected, to prevent the future devel-
opment of HIV cross-resistance. Entecavir or tenofovir monothera-
py should not be used in patients with HBV/HIV co-infection due 
to the development of resistant HIV. Patients who need treatment 
for both HIV and HBV should be treated with antiviral agents that 
are effective against both viruses, such as tenofovir/emtricitabine, 
tenofovir or lamivudine, as highly active anti-retroviral therapy 
(HAART).531-533 When HAART regimens are altered, antiviral 
agents that are effective against HBV should be included to avoid 
HBV reactivation, except in patients who meet the criteria for dis-
continuation of anti-HBV treatment.
[Recommendation]
1.  HBV/HIV-coinfected patients who exhibit ALT elevation due 
to HBV should be considered for HBV treatment. (B1)
2.  Patients who are not indicated for HAART at present or in 
the near future should receive the standard treatment for 
CHB. In such cases, NAs that do not affect HIV proliferation 
should be used to prevent the future development of HIV 
cross-resistance. (B1)
3.  Patients who need treatment for both HIV and HBV should be 
treated with HAART agents effective against both viruses; 
e.g., tenofovir/emtricitabine or tenofovir plus lamivudine. (B1)
Female patients of childbearing age
1. Treatment before pregnancy
When planning treatment for females of child-bearing age, spe-
cial considerations for the fetus and the duration of treatment are 
needed in addition to the aforementioned general considerations. 
For example, IFN preparations are preferred in female patients 
who are planning pregnancy as the period of treatment is more 
clearly defined. However, the IFN side effect of fetal malforma-
tions makes it contraindicated during pregnancy, and so it must 
be recommended in combination with contraception during the 
therapy and until 6 month after cessation of therapy. Females 
who want to be pregnant should be treated with antiviral agents 
that belong to pregnancy category B drugs (which, according to 
the results of animal studies, carry no teratogenic or embryogenic 
risk and for which there have been no controlled human studies 
or for which animal studies may indicate a risk, but controlled hu-
man studies refute the findings). Tenofovir and telbivudine belong 
to pregnancy category B, while entecavir, adefovir and lamivudine 
belong to pregnancy category C drugs (drugs that exert terato-
genic or embryocidal effects in animals and for which there are no 
controlled studies in humans).15 
2. Treatment during pregnancy
Pregnant females with chronic HBV infection are usually in the 
immune-tolerance phase,534 and changes in the maternal immune 
system during pregnancy, such as a shift in the Th1-Th2 balance 
toward a Th2 response, lead to an increase in the HBV DNA level 
and a reduction in the ALT level.535 These immune responses are 
restored after delivery, thereby causing a reduction in the HBV 
DNA level and ALT elevation, and so careful monitoring is need-
ed.535-537 
The optimal antiviral treatment strategy during pregnancy is 
based on the aforementioned general principles for the treatment 
of CHB. However, all decisions regarding the timing and duration 
of treatment in pregnancy should include an analysis of the risks 
and benefits for both the mother and fetus. In addition, pregnant 
females often experience worsening of liver disease unrelated to 
HBV infection (e.g., acute fatty liver of pregnancy), which is diffi-
cult to discriminate from an HBV flare-up. Thus, antiviral treat-
ment should be considered when liver disease is present (e.g., 
jaundice or prolongation of PT), and the HBV DNA level meets the 
general criteria for antiviral treatment.
When starting antiviral therapy during pregnancy, category B 
drugs are recommended. Safety data of antiviral agents during 
pregnancy can be found at the Antiretroviral Pregnancy Registry 
(APR; http://www.apregistry.com). The APR is an international, 
voluntary, prospective registry that reports the rate of birth de-
fects of newborns born to mothers receiving antiretroviral therapy, 
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and it contains a considerable amount of data on lamivudine and 
tenofovir. According to the APR, the rates of birth defects among 
females exposed to lamivudine and tenofovir in the first trimester 
(3.1% and 2.4% of live births, respectively) are similar to that in 
the general population (2.7%), as reported by the CDC birth de-
fect surveillance system. Few cases related to other drugs such as 
telbivudine and entecavir have been reported. However, since the 
APR is designed to report only defects identified at birth, it may 
not contain accurate data on developmental anomalies (e.g., car-
diac or neurologic defects). 
Oral antiviral agents may cause mitochondrial toxicity by inhibit-
ing mitochondrial DNA replication. It is difficult to estimate their 
effects on the fetus, especially in the developmental stages.224 
Thus, based on considerations of fetal safety oral antiviral agents 
should not be administered, especially in the first trimester of 
pregnancy. However, the decision about whether to discontinue 
drugs in patients receiving treatment with oral antiviral agents 
should be individualized. One retrospective study showed that 
~14% of pregnant females with active chronic hepatitis B without 
antiviral therapy can progress to hepatic failure and have a risk of 
maternal or fetal death, so appropriate antiviral therapy should be 
considered in pregnant females in the active phase of chronic 
hepatitis B.538 
In childbearing females who require treatment with an oral an-
tiviral agent against HBV, pregnancy category B drugs such as te-
nofovir can be considered if the patient wants to become preg-
nant. In females already receiving antiviral therapy with a 
category C drug who want to become pregnant, the category C 
drug should be changed to a category B drug, such as tenofovir. 
In the first trimester of pregnancy, pregnant females with mild 
chronic hepatitis B and undetectable HBV DNA (<60 IU/mL) may 
be considered for temporary drug discontinuation with careful 
monitoring for HBV reactivation. Meanwhile, females who be-
come pregnant while on category C drugs should change to cate-
gory B drugs if continuous antiviral therapy is needed.539 
As little about whether or not antiviral agents are secreted into 
breast milk is known, and the effects on babies of antiviral agents 
in breast milk is unclear, breast-feeding is not currently recom-
mended.
Prevention of vertical transmission with antiviral 
drugs
A high maternal HBV DNA level is associated with a high rate of 
failure of neonatal passive-active immunoprophylaxis.540-543 In a 
double-blind, randomized controlled trial, pregnant females with 
high serum HBV DNA levels (>103 Meq/mL [~109 cpm]) were giv-
en lamivudine from week 32 of gestation to week 4 postpartum in 
addition to neonatal passive-active immunoprophylaxis. HBsAg 
positivity was present in 18% and 39% of 1-year-old infants from 
lamivudine- and placebo-treated mothers, respectively (P=0.014)544 
No safety concerns were noted in the lamivudine-treated mothers 
and their newborns. However, these data should be interpreted 
with caution due to the high dropout rates, especially in the pla-
cebo group (13% in the lamivudine group and 31% in the placebo 
group). A prospective study included pregnant females with 
HBeAg-positive and high serum HBV DNA levels (>107 copies/mL) 
who were treated with lamivudine from week 24 to week 32 in 
addition to neonatal passive-active immunoprophylaxis as the 
treatment group. The HBsAg-positivity rates of infants at 1 year 
after birth were significantly different: 0% (0/94) in the treatment 
group and 7.7% (7/91) in the placebo group.545 Another prospec-
tive study included pregnant females with high serum HBV DNA 
levels (>106 copies/mL) treated with telbivudine from week 12–30 
to birth in addition to neonatal passive-active immunoprophylaxis 
as the treatment group. The HBsAg-positivity rates of infants at 6 
months after birth were significantly different: 0% (0/54) in the 
treatment group and 8.6% (3/35) in the placebo group.546 Anoth-
er prospective controlled study included pregnant females with 
high serum HBV DNA levels (>107 copies/mL) treated with telbivu-
dine from weeks 20 to 32 of gestation to week 4 postpartum in 
addition to neonatal passive-active immunoprophylaxis. HBsAg 
positivity was present in none (0/132) of the 6-month-old infants 
from telbivudine-treated mothers, whereas it was present in 8% 
(7/88) of those from placebo-treated mothers.547 Another pro-
spective study included pregnant females with high serum HBV 
DNA levels (>107 copies/mL) treated with tenofovir or lamivudine 
from week 32 to week 4–12 postpartum in addition to neonatal 
passive-active immunoprophylaxis as the treatment group. The 
HBsAg-positivity rates of infants at 9 months after birth were sig-
nificantly different: 1% (1/87) in the treatment group and 20% 
(2/10) in the placebo group.548 The prevalence of safety issues did 
not differ significantly between the two groups. These studies im-
ply that antiviral medication in the late stage of pregnancy is likely 
to reduce the rate of vertical transmission. However, the decision 
about whether or not to treat should be individualized in patients 
not indicated for the treatment of HBV, based on the treatment 
duration, stopping point, possible appearance of drug-resistant 
strains, and the patient’s preferences.
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[Recommendations]
1.  Peginterferon-α has an advantage in female patients who 
are planning pregnancy due to its finite treatment duration. 
(C1) However, the side effects pertaining to fetal malforma-
tions make peginterferon-α treatment contraindicated dur-
ing pregnancy, and it should be recommended in combina-
tion with contraception. (A1)
2.  When antiviral treatment is needed during pregnancy, 
pregnancy category B NAs are recommended. (B1)
3.  The antiviral treatment strategy during pregnancy is based 
on the general principles of CHB treatment; however, deci-
sions should be based on analysis of the risks and benefits 
for both the mother and fetus. (C1)
4.  Breastfeeding is not recommended in females receiving 
treatment with NAs. (C1)
Children and adolescents
Providing HBIG and HBV vaccine to newborns of HBsAg-positive 
mothers within 12 h of birth can prevent 90–95% of cases of 
perinatal infection. Ninety percent of infants infected as a neo-
nates progress to chronic infection. Most children remain in the 
immune-tolerant phase until late childhood or adolescence. How-
ever, some children progress to the immune-reactive phase. The 
spontaneous HBeAg seroconversion rate in immune-tolerant Ko-
rean children was 4.6%, 7.1%, and 28.0% for patients aged <6, 
6-12, >12 years, respectively.549 A Taiwanese study reported an-
nual spontaneous HBeAg seroconversion rates of 2% and 4–5% 
in children younger than 3 years and older than 3 years, respec-
tively.550 Children who are in the immune-reactive phase—with 
increased ALT levels and histologic findings of liver inflammation 
and fibrosis—are usually asymptomatic. Long-term treatment in 
children with CHB is expected, and a prudent decision should be 
made based on the adverse effects of the drugs and the potential 
for viral resistance to affect future therapies. The treatment win-
dow should not be missed because cirrhosis can occur in their 20s 
and HCC later in life. The goals of therapy are to suppress viral 
replication, reduce liver inflammation, reverse liver fibrosis, and 
prevent cirrhosis and HCC.
Treating children in the immune-tolerant phase is not beneficial, 
and there is a high risk of development of drug resistance, which 
would limit treatment options in later life. Children with a persis-
tent elevated serum ALT level should be evaluated for viral active 
replication, including measurement of HBV DNA levels. HBeAg-
positive children should be considered for treatment when their 
serum ALT levels are above 2 ULN for at least 6 months and their 
HBV DNA levels are above 20,000 IU/mL.551 Acute elevation of liv-
er enzymes with an ALT level of >5 ULN may be followed by 
spontaneous HBeAg seroconversion. It is therefore reasonable to 
delay treatment for an observation period of at least 3 months if 
there is no concern regarding hepatic decompensation. Children 
with moderate-to-severe necroinflammation or periportal fibrosis 
in a liver biopsy are recommended for treatment. The decision to 
treat is based on factors such as age, liver biopsy findings, and 
family history of HBV-associated cirrhosis or HCC. In obese chil-
dren it is important to remember that ALT elevations may be due 
to fatty liver disease.552 The responses to interferon-α and lamivu-
dine are better in children with higher activity scores in a liver bi-
opsy.553,554
A randomized controlled trial of interferon-α therapy involving 
children aged 1 to 17 years found that 36% of those with a base-
line ALT level of at least 2 ULN became negative for HBeAg at the 
end of treatment. HBsAg seroconversion occurred in 10% of the 
treated children.553 Factors predictive of a positive response 
among children are being younger than 5 years,555 having a low 
serum HBV DNA level, and having active inflammation in a liver 
biopsy.553 After 5 years of observation, the rate of HBeAg sero-
conversion did not differ between the treatment and control 
groups. However, loss of HBsAg occurred in 25% of children who 
responded to treatment, but in none of the children in the nonre-
sponse and control groups.556 The recommended treatment regi-
men for interferon-α is 6 MU/m2 three times per week by subcuta-
neous injection for 6 months. Interferon-α is approved in children 
older than 12 months, and its advantages include the finite dura-
tion of treatment and no development of viral resistance. The ad-
verse effects include fever, flu-like symptoms, bone marrow sup-
pression, depression, and transient growth suppression. 
Interferon-α is contraindicated in children with decompensated 
cirrhosis and autoimmune disease. Clinical trials of peginterferon 
in children with CHB are ongoing. The efficacy and safety of pe-
ginterferon were demonstrated in children with chronic hepatitis 
C, and an update of the Swedish national recommendations for 
the treatment of CHB recommends the use of peginterferon (100 
μg/m2 weekly) in children.557  
A randomized controlled study of lamivudine involving children 
aged 2–17 years found that loss of HBeAg at 52 weeks of treat-
ment occurred in 34% of those with a baseline ALT level of at 
least 2 ULN, and that the resistance rate was 18%.558 The HBeAg 
seroconversion rate after 2 years of therapy was 54% in children 
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without lamivudine-resistant virus. The resistance rate was 64% 
in children who received lamivudine for 3 years. Lamivudine treat-
ment for >3 years did not significantly increase seroconversion 
rates and increased the incidence of viral resistance.559 Studies of 
Korean children found that the HBeAg seroconversion rates after 
2 and 3 years of treatment were 65% and 70%, respectively.560,561 
Loss of HBsAg was observed in 20% of children after 2 years of 
lamivudine treatment, and the resistance rates at 1 and 2 years of 
treatment were 10% and 23%, respectively. Factors associated 
with a response were elevated baseline ALT, high baseline histol-
ogy-activity-index score,554 and being younger than 7 years.560 
Long-term durability of HBeAg seroconversion was observed in 
more than 90% of the subjects after they had taken lamivudine 
for at least 2 years.562 Lamivudine is orally administered at a dose 
of 3 mg/kg/day, with a maximum of 100 mg/day.552 Lamivudine 
treatment should be continued for at least 1 year, and it is desir-
able to continue treatment for 1 year after HBeAg seroconversion. 
If lamivudine resistance develops, it should be treated in accor-
dance with the guidelines for antiviral resistance management in 
adults. 
 A randomized controlled study of 173 HBeAg-positive children 
aged 2–17 years showed undetectable HBV DNA and a normal ALT 
level after 48 weeks of adefovir treatment in 23% of 12- to 
17-year-old subjects, but there was no significant difference be-
tween adefovir and placebo in those aged 2–11 years. The HBeAg 
seroconversion rate in the adefovir group and placebo group was 
16% and 5%, respectively (P=0.051). No subject developed adefo-
vir resistance.563 Continuation of adefovir treatment for a further 4 
years was safe. Resistance to adefovir was observed in one child.564
Entecavir and tenofovir are potent HBV inhibitors with a high bar-
rier to resistance. Entecavir is considered the first-line therapy in 
children older than 2 years and tenofovir in those older than 12 
years. A randomized controlled trial of tenofovir in adolescents aged 
12 to 17 years reported that the rate of a virologic response (HBV 
DNA <400 copies/mL) at week 72 was significantly higher in pa-
tients (n=52) who received tenofovir than those (n=54) who re-
ceived placebo (89% vs. 0%).565 No resistance to tenofovir devel-
oped through week 72. The rate of grade 3/4 adverse events was 
higher among patients treated with placebo (24%) than those 
treated with tenofovir (10%). In a randomized controlled study in-
volving 180 children aged 2 to 17 years with HBeAg-positive CHB, 
the HBeAg seroconversion and HBV DNA <50 IU/mL rates at 
week 48 were significantly higher with entecavir than placebo 
(24.2% versus 3.3%). The cumulative probability of entecavir re-
sistance at 1 and 2 years was 0.6% and 2.6%, respectively. Ente-
cavir showed no difference in safety compared with placebo.566 
[Recommendations]
1. HBeAg-positive CHB children with an HBV DNA level 
>20,000 IU/mL and HBeAg-negative CHB children with an 
HBV DNA level >2,000 IU/mL should be considered for 
treatment when the AST or ALT level is > 2 ULN for at least 6 
months, or moderate-to-severe necroinflammation or peri-
portal fibrosis is evident in a liver biopsy. (A1)
2. Tenofovir, entecavir or interferon-α is the first-line therapy 
in children with CHB. (B1) Data on peginterferon are cur-
rently scarce, but its use in children can be based on the re-
sults of studies involving adults. (C1)
3. If antiviral resistance develops, it should be treated in ac-
cordance with the guidelines for antiviral resistance man-
agement in adults. (B1)
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